Nutra Pharma (NPHC) 10-K 13 Apr 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Apr. 13, 2015	Jun. 30, 2014
Document And Entity Information
Entity Registrant Name	NUTRA PHARMA CORP.
Entity Central Index Key	1119643
Document Type	10-K
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$6,006,842
Entity Common Stock, Shares Outstanding		1,511,950,321
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash	$15,530	$4,640
Accounts receivable	127,368	11,141
Inventory	46,945	5,000
Prepaid expenses and other current assets	151,968	68,091
Total current assets	341,811	88,872
Property and equipment, net	29,490	24,534
Other assets	15,955	15,955
Total assets	387,256	129,361
Current liabilities:
Accounts payable	1,243,997	1,019,130
Accrued expenses	1,019,673	957,682
Due to officers	540,877	689,588
Derivative warrant liability	186,549	323,172
Other debt, net of discounts of $2,611 and $0, respectively	960,921	1,359,238
Total current liabilities	3,952,017	4,348,810
Convertible debts	30,000
Total liabilities	3,982,017	4,348,810
Commitments and Contingencies (See Note 10)
Stockholders' deficit:
Common stock, $0.001 par value, 2,000,000,000 shares authorized; 1,470,631,255 and 1,004,313,019 shares issued and outstanding at December 31, 2014 and 2013	1,470,631	1,004,313
Additional paid-in capital	39,454,413	36,763,058
Accumulated deficit	-44,519,805	-41,986,820
Total stockholders' deficit	-3,594,761	-4,219,449
Total liabilities and stockholders' deficit	$387,256	$129,361

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	2,000,000,000	2,000,000,000
Common stock, shares issued	1,470,631,255	1,004,313,019
Common stock, shares outstanding	1,470,631,255	1,004,313,019
Other debt, net of discounts	$2,611	$0

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Net sales	$594,505	$104,835
Cost of sales	114,300	41,165
Gross profit	480,205	63,670
Operating expenses:
Selling, general and administrative - including stock based compensation of $511,668 and $1,391,979, respectively	2,682,479	2,425,108
Total other costs and expenses	2,682,479	2,425,108
Net Loss from Operations	-2,202,274	-2,361,438
Other Expenses
Interest expense	-128,104	-157,376
Change in fair value of derivatives	-208,190	-1,135,677
Loss on settlement of debt and accounts payable, net	5,583	-707,651
Other income		19,178
Total other income (expense), net	-330,711	-1,981,526
Net loss before income taxes	-2,532,985	-4,342,964
Provision for income taxes
Net loss	($2,532,985)	($4,342,964)
Net loss per share - basic and diluted	$0	($0.01)
Weighted average number of shares outstanding during the period - basic and diluted	1,225,712,524	743,492,967

Consolidated_Statements_of_Ope1

Consolidated Statements of Operations (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Stock based compensation	$511,668	$1,391,979

Consolidated_Statements_of_Cha

Consolidated Statements of Changes in Stockholders' Deficit (USD $)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning Balance at Dec. 31, 2012	$561,774	$33,505,739	($37,643,856)	($3,576,343)
Beginning Balance, Shares at Dec. 31, 2012	561,773,778
Issuance of common stock in exchange for services to consultants	71,600	669,770		741,370
Issuance of common stock in exchange for services to consultants, Shares	71,600,000
Issuance of common stock in exchange for services to directors and employees	35,630	472,090		507,720
Issuance of common stock in exchange for services to directors and employees, Shares	35,630,000
Common stock issued in private placement	42,000	98,000		140,000
Common stock issued in private placement, Shares	42,000,000
Common stock issued in exchange for related party debt	50,000	112,500		162,500
Common stock issued in exchange for related party debt, Shares	50,000,000
Common stock issued for modification of debt	5,750	24,550		30,300
Common stock issued for modification of debt, Shares	5,750,000
Common stock issued for conversion of debt	193,759	1,453,073		1,646,832
Common stock issued for conversion of debt, Shares	193,759,241
Common stock issued for settlement of AP	42,800	423,200		466,000
Common stock issued for settlement of AP, Shares	42,800,000
Common stock issued to note holder	1,000	2,977		3,977
Common stock issued to note holder, Shares	1,000,000
In-kind contribution of interest		1,159		1,159
Net loss			-4,342,964	-4,342,964
Ending Balance at Dec. 31, 2013	1,004,313	36,763,058	-41,986,820	-4,219,449
Ending Balance, Shares at Dec. 31, 2013	1,004,313,019
Issuance of common stock in exchange for services to consultants	27,775	168,773		196,548
Issuance of common stock in exchange for services to consultants, Shares	27,775,000
Issuance of common stock in exchange for services to directors and employees	54,092	270,460		324,552
Issuance of common stock in exchange for services to directors and employees, Shares	54,092,000
Common stock issued in private placement	12,000	48,000		60,000
Common stock issued in private placement, Shares	12,000,000
Common stock issued in exchange for related party debt	50,000	50,000		100,000
Common stock issued in exchange for related party debt, Shares	50,000,000
Common stock issued for modification of debt	2,500	39,825		42,325
Common stock issued for modification of debt, Shares	2,500,000
Common stock issued for conversion of debt	135,578	808,326		943,904
Common stock issued for conversion of debt, Shares	135,578,070
Common stock issued for settlement of AP	182,373	1,292,306		1,474,679
Common stock issued for settlement of AP, Shares	182,373,166
Common stock issued to note holder	2,000	13,665		15,665
Common stock issued to note holder, Shares	2,000,000
In-kind contribution of interest
Net loss			-2,532,985	-2,532,985
Ending Balance at Dec. 31, 2014	$1,470,631	$39,454,413	($44,519,805)	($3,594,761)
Ending Balance, Shares at Dec. 31, 2014	1,470,631,255

Statements_of_Cash_Flows_Unaud

Statements of Cash Flows (Unaudited) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Cash collected from customers	$1,558,124	$146,832
Cash paid for commission	-748,376
Cash paid to suppliers	-107,747	-49,881
Cash paid to employees	-100,095	-57,821
Interest paid	-34,497	-70,130
Loan origination fees paid	-14,350
Other operating cash payments	-701,188	-500,038
Net cash used in operating activities	-148,129	-531,038
Cash flows from investing activities:
Acquisition of property and equipment	-21,550
Net cash used in investing activities:	-21,550
Cash flows from financing activities:
Common stock sold for cash	60,000	140,000
Loans from officers	86,464	181,718
Repayment of officers loans	-161,969	-83,600
Repayments of notes payable-related party	-60,000
Proceeds from convertible notes	50,000	225,000
Proceeds from other notes payable	225,000	75,000
Repayments of other notes payable	-18,926
Repayments of notes payable-related party		-10,000
Net cash provided by financing activities	180,569	528,118
Net increase in cash	10,890	-2,919
Cash - beginning of period	4,640	7,559
Cash - end of period	15,530	4,640
Cash flows from operating activities:
Net loss	-2,532,985	-4,342,964
Adjustments to reconcile net loss to net cash used in operating activities:
Shares issued for services	1,158,417	707,650
Loss on note payable default
Depreciation and amortization	16,594	14,981
Stock-based compensation	511,668	1,391,979
Stock issued for loan extension	42,325	30,300
Change in fair value of derivative	208,190	1,135,677
In-kind contribution of interest		1,159
Amortization of loan discount	15,254	3,977
Decrease (increase) in accounts receivables	-116,227	27,173
Decrease (increase) in inventory	-41,945	-5,000
Increase in due from related party
Decrease (increase) in prepaid stock-based compensation
Increase in prepaid expenses and other assets	-76,645	-9,446
Increase in accounts payable	558,628	429,808
Increase in accrued expenses	108,597	83,669
Net cash used in operating activities	-148,129	-531,038
Non cash Financing and Investing:
Stock issued in settlement of accounts payable	320,000	709,146
Shares issued to satisfy debt	943,904	1,646,832
Shares issued to satisfy debt-related party	100,000	162,500
Discounts on notes payable	$15,665

BASIS_OF_PRESENTATION_AND_SUMM

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	1. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Organization
	Nutra Pharma Corp. ("Nutra Pharma"), is a holding company that owns intellectual property and operates in the biotechnology industry. Nutra Pharma incorporated under the laws of the state of California on February 1, 2000, under the original name of Exotic-Bird.com.
	Through its wholly-owned subsidiary, ReceptoPharm, Inc. (“ReceptoPharm”), Nutra Pharma conducts drug discovery research and development activities. In October 2009, Nutra Pharma launched its first consumer product called Cobroxin®, an over-the-counter pain reliever designed to treat moderate to severe chronic pain. In May 2010, Nutra Pharma launched its second consumer product called Nyloxin®, an over-the-counter pain reliever that is a stronger version of Cobroxin® and is designed to treat severe chronic pain. In December 2014, we launched Pet Pain-Away, an over-the-counter pain reliever designed to treat pain in cats and dogs.
	Basis of Presentation and Consolidation
	The accompanying consolidated financial statements include the results of Nutra Pharma and its wholly-owned subsidiaries Designer Diagnostics Inc. and ReceptoPharm (collectively "the Company", “us”, “we” or “our”). We operate as one reportable segment. All intercompany transactions and balances have been eliminated in consolidation.
	Liquidity and Going Concern
	Our Consolidated Financial Statements are presented on a going concern basis, which contemplate the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring, significant losses from operations, and have an accumulated deficit of $44,519,805 at December 31, 2014. In addition, we had respective working capital and stockholders’ deficits at December 31, 2014 of $3,610,206 and $3,594,761, respectively.
	There is substantial doubt regarding our ability to continue as a going concern which is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate.
	As of December 31, 2014, we do not have sufficient cash to sustain our operations for the next year and will require additional financing in order to execute our operating plan and continue as a going concern. Since our sales are not currently adequate to fund our operations, we continue to rely principally on debt and equity funding; however proceeds from such funding have not been sufficient to execute our business plan. Our plan is to attempt to secure adequate funding until sales of our pain products are adequate to fund our operations. We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form. In the event that these financing sources do not materialize, or if we are unsuccessful in increasing our revenues and profits, we will be unable to implement our current plans for expansion, repay our obligations as they become due and continue as a going concern.
	The accompanying Consolidated Financial Statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.
	Use of Estimates
	The accompanying Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as going concern, the recoverability of inventories and long-lived assets, and the valuation of stock-based compensation and certain debt and warrant liabilities. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known.
	Revenue Recognition
	In general, we record revenue when persuasive evidence of an arrangement exists, services have been rendered or product delivery has occurred, the sales price to the customer is fixed or determinable, and collectability is reasonably assured. Provision for sales returns is estimated based on our historical return experience. Revenue is presented net of returns and allowances for returns.
	The Company collects 100% of the cash proceeds from the sale of its product by its distributor, remits a portion of the cash proceeds received back to the distributor and records the sale on a net basis. In the year ended December 31, 2014 and 2013, the Company collected $1,558,124 and $146,832 in gross receipts and recorded $594,505 and $104,835 as net sales.
	Accounting for Shipping and Handling Costs
	The Company records shipping and handling costs incurred in cost of sales.
	Cash and Cash Equivalents
	We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents.
	Accounts Receivable and Allowance for Doubtful Accounts
	The Company grants credit without collateral to its customers based on the Company’s evaluation of a particular customer’s credit worthiness. In addition, allowances for doubtful accounts are maintained for potential credit losses based on the age of the accounts receivable and the results of the Company’s periodic credit evaluations of its customers’ financial condition. Accounts receivable are written off after collection efforts have been deemed to be unsuccessful. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against the provision for doubtful accounts expense. The Company generally does not charge interest on accounts receivable.
	Accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts.
	Inventories
	Inventories, which are stated at the lower of average cost or market, and consist of packaging materials, finished products, and raw venom that is utilized to make the API (active pharmaceutical ingredient). The raw unprocessed venom has an indefinite life for use. The Company regularly reviews inventory quantities on hand.  If necessary it records a provision for excess and obsolete inventory based primarily on its estimates of component obsolescence, product demand and production requirements. Write-downs are charged to cost of goods sold.  We performed evaluations of our inventory during the year ended December 31, 2014 and 2013 and determined no allowances need to be recorded.
	Financial Instruments and Concentration of Credit Risk
	Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain warrant and convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transactions in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at a measured fair value.
	Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not hold or issue financial instruments for trading purposes. In addition, for the year ended December 31, 2014, no customers accounted for more than 10% of the Company’s total revenues. For the year ended December 31, 2013, there were two customers that accounted for 19.6% and 15.3% of the total revenues, respectively. During 2014 and 2013, the Company purchased 100% of its venom from one vendor.
	Derivative Financial Instruments
	The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. For embedded derivatives, the Company uses a Dilution-Adjusted Black-Scholes method to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.
	Convertible Debt
	The Company bifurcates the embedded derivative element in convertible debt which contain conversion features which are not considered to be conventional convertible debt.  The convertible debt is recorded at the bifurcated amount after reducing the proceeds for the liability related to the embedded call provision which is accounted for separately in the accompanying balance sheets.  After recording the initial amount of the debt, the discount related to the bifurcated embedded derivative is amortized as additional interest expense over the term of the debt with the resulting debt discount being accreted over the term of the note.
	Property and Equipment and Long-Lived Assets
	Property and equipment is recorded at cost. Expenditures for major improvements and additions are added to property and equipment, while replacements, maintenance and repairs which do not extend the useful lives are expensed. Depreciation is computed using the straight-line method over the estimated useful lives of the assets of 3 – 7 years.
	Property and equipment consists of the following at December 31,
			2014		2013
	Computer equipment	$	24,208	$	21,918
	Furniture and fixtures		34,757		34,757
	Lab equipment		42,129		42,129
	Telephone equipment		12,421		12,421
	Office equipment – other		16,138		2,629
	Leasehold improvements		73,168		67,417
	Total		202,821		181,271
	Less: Accumulated depreciation and amortization		-173,331		-156,737
	Property and equipment, net	$	29,490	$	24,534
	We review our long-lived assets for recoverability if events or changes in circumstances indicate the assets may be impaired. At December 31, 2014, we believe the carrying values of our long-lived assets are recoverable. Depreciation expense for the years ended December 31, 2014 and 2013 was $16,594 and $14,981, respectively.
	Advertising
	All advertising costs are expensed as incurred.  Advertising costs were approximately $6,156 and $900 for the years ended December 31, 2014 and 2013, respectively.
	Income Taxes
	We compute income taxes in accordance with Financial Accounting Standard Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 740, Income Taxes (“ASC Topic 740”). Under ASC Topic 740, deferred taxes are recognized for the tax consequences of temporary differences by applying enacted statutory rates applicable to future years to differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities. Also, the effect on deferred taxes of a change in tax rates is recognized in income in the period that included the enactment date. Temporary differences between financial and tax reporting arise primarily from the use of different methods to record bad debts and /or sales returns, and inventory reserves.
	On an annual basis, we evaluate tax positions that have been taken or are expected to be taken in our tax returns to determine if they are more than likely to be sustained if the taxing authority examines the respective position.  As of December 31, 2014 and 2013, we do not believe we have a need to record any liabilities for  uncertain tax positions or provisions for interest or penalties related to such  positions.
	Since inception, we have been subject to tax by both federal and state taxing authorities. Until the respective statutes of limitations expire (which may be as much as 20 years while we have unused net operation losses), we are subject to income tax audits in the jurisdictions in which we operate. The Company’s 2011 to 2014 tax returns are subject to examination by Internal Revenue Services and State Taxing Agency’s.
	Stock-Based Compensation
	We account for stock-based compensation in accordance with FASB ASC Topic 718, Stock Compensation (ASC Topic 718). ASC Topic 718, which requires that the cost resulting from all share-based transactions be recorded in the financial statements over the respective service periods. It establishes fair value as the measurement objective in accounting for share-based payment arrangements and requires all entities to apply a fair-value-based measurement in accounting for share-based payment transactions with employees. The statement also establishes fair value as the measurement objective for transactions in which an entity acquires goods or services from non-employees in share-based payment transactions.
	Net Loss Per Share
	Net loss per share is calculated in accordance with ASC Topic 260, Earnings per Share. Basic loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted loss per share is calculated by dividing net loss by the weighted average number of common shares and dilutive common stock equivalents outstanding. During periods in which we incur losses, common stock equivalents, if any, are not considered, as their effect would be anti-dilutive or have no effect on earnings per share. Any common shares issued as of a result of the exercise of stock options and warrants would come from newly issued common shares from our remaining authorized shares. As of December 31, 2014 and 2013, the following items were not included in dilutive loss as the effect is anti-dilutive:
			2014		2013
	Options and warrants		64,266,667		154,916,667
	Convertible notes payable		56,817,342		98,506,398
	Total		121,084,009		253,423,065
	Reclassifications
	Certain amounts in the 2013 Consolidated Financial statements have been reclassified to conform to the current period presentation.
	Recent Accounting Pronouncements
	ASU 2014 - 09
In June 2014, FASB issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers”. The update gives entities a single comprehensive model to use in reporting information about the amount and timing of revenue resulting from contracts to provide goods or services to customers. The proposed ASU, which would apply to any entity that enters into contracts to provide goods or services, would supersede the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance throughout the Industry Topics of the Codification. Additionally, the update would supersede some cost guidance included in Subtopic 605-35, Revenue Recognition – Construction-Type and Production-Type Contracts. The update removes inconsistencies and weaknesses in revenue requirements and provides a more robust framework for addressing revenue issues and more useful information to users of financial statements through improved disclosure requirements. In addition, the update improves comparability of revenue recognition practices across entities, industries, jurisdictions, and capital markets and simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. The update is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. We are currently reviewing the provisions of this ASU to determine if there will be any impact on our results of operations, cash flows or financial condition.
ASU 2014-12
In June 2014, FASB issued Accounting Standards Update (“ASU”) No. 2014-12, “Compensation – Stock Compensation ( Topic 718 ); Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period”. The amendments in this ASU apply to all reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target that affects vesting could be achieved after the requisite service period. The amendments require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Topic 718 as it relates to awards with performance conditions that affect vesting to account for such awards. For all entities, the amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted. The effective date is the same for both public business entities and all other entities.
Entities may apply the amendments in this ASU either (a) prospectively to all awards granted or modified after the effective date or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. If retrospective transition is adopted, the cumulative effect of applying this Update as of the beginning of the earliest annual period presented in the financial statements should be recognized as an adjustment to the opening retained earnings balance at that date. Additionally, if retrospective transition is adopted, an entity may use hindsight in measuring and recognizing the compensation cost. We are currently reviewing the provisions of this ASU to determine if there will be any impact on our results of operations, cash flows or financial condition.
ASU 2014-15
In August 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-15 on “Presentation of Financial Statements Going Concern (Subtopic 205-40) – Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. Currently, there is no guidance in U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. The amendments in this Update provide that guidance. In doing so, the amendments are intended to reduce diversity in the timing and content of footnote disclosures. The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in this Update are effective for public and non-public entities for annual periods ending after December 15, 2016. Early adoption is permitted. We are currently reviewing the provisions of this ASU to determine if there will be any impact on our results of operations, cash flows or financial condition.
All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	2. FAIR VALUE MEASUREMENTS
	Certain assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2013 are measured in accordance with FASB ASC Topic 820-10-05, Fair Value Measurements. FASB ASC Topic 820-10-05 defines fair value, establishes a framework for measuring fair value and expands the disclosure requirements regarding fair value measurements for financial assets and liabilities as well as for non-financial assets and liabilities that are recognized or disclosed at fair value on a recurring basis in the financial statements.
	The statement requires fair value measurement be classified and disclosed in one of the following three categories:
	Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
	Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and
	Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).
	The following table summarizes our financial instruments measured at fair value as of December 31, 2014 and 2013:
			Fair Value Measurements at December 31, 2014
	Liabilities:		Total		Level 1		Level 2		Level 3
	Warrant liability	$	186,549	$	-	$	-	$	186,549
	Convertible notes at fair value	$	330,277	$	-	$	-	$	330,277
			Fair Value Measurements at December 31, 2013
	Liabilities:		Total		Level 1		Level 2		Level 3
	Warrant liability	$	323,172	$	-	$	-	$	323,172
	Convertible notes at fair value	$	767,056	$	-	$	-	$	767,056
	The following table shows the changes in fair value measurements using significant unobservable inputs (Level 3) during the years ended December 31, 2014 and 2013:
	Description		2014		2013
	Beginning balance	$	323,172	$	18,727
	Purchases, issuances, and settlements		18,551		243,147
	Day one loss on value of hybrid instrument		-		729,093
	Total gain included in earnings (1)		-155,174		-667,795
	Ending balance	$	186,549	$	323,172
	(1)   The gain or loss related to the revaluation of our warrant liability is included in “Change in fair value of derivatives” in the accompanying consolidated statement of operations.
	The Company values its warrants using a Dilution-Adjusted Black-Scholes Model.  Assumptions used include (1) 0.25% to 1.65% risk-free rate, (2) warrant life is the remaining contractual life of the warrants, (3) expected volatility of 161% to 174% (4) zero expected dividends (5) exercise price set forth in the agreements (6) common stock price of the underlying share on the valuation date, and (7) number of shares to be issued if the instrument is converted.
	The following table summarizes the significant terms of each of the debentures for which the entire hybrid instrument is recorded at fair value as of December 31, 2014 and 2013:
	Debenture		Face		Interest		Default		Conversion Price - Lower of Fixed Price or Percentage of VWAP for Look-back Period		Look-back
	Issuance Year		Amount		Rate		Interest				Period
							Rate		Anti-Dilution	%
									Adjusted Price
	2014		215,386		8%-20%		n/a		$0.0028-$0.0050	50%-85%	10 to 30 Days
	2013		564,376		8%-20%		n/a		$0.0036-$0.0064	50%-85%	10 to 30 Days
	The following table shows the changes in fair value measurements using significant unobservable inputs (Level 3) during the years ended December 31, 2014 and 2013 for the Convertible Notes:
			Years Ended December 31,
			2014		2013
	Description
	Beginning balance	$	767,057	$	588,091
	Purchases, issuances, and settlements		162,311		751,419
	Day one loss on value of hybrid instrument		423,340		1,656,802
	(Gain) loss from change in fair value		-78,527		-582,423
	Conversion to common stock		-943,904		-1,646,832
	Ending balance	$	330,277	$	767,057

INVENTORIES

INVENTORIES	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
INVENTORIES	3. INVENTORIES
	Inventories are valued at the lower of cost or market on an average cost basis. At December 31, 2014 and 2013, inventories were as follows:
			2014		2013
	Raw Materials	$	16,805	$	5,000
	Finished Goods		30,140	$	-
	Total Inventories	$	46,945	$	5,000
	The Company regularly reviews inventory quantities on hand.  If necessary, the Company records a provision for excess and obsolete inventory based primarily on its estimates of component obsolescence, product demand and production requirements. Write-downs and write-offs are charged to cost of goods sold.  We performed evaluations of our inventory during 2014 and 2013, the Company did not experience any write downs or write offs.

SETTLEMENT_OF_ACCOUNTS_AND_NOT

SETTLEMENT OF ACCOUNTS AND NOTE PAYABLE	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
SETTLEMENT OF ACCOUNTS AND NOTE PAYABLE	4. SETTLEMENT OF ACCOUNTS AND NOTE PAYABLE
	At December 20, 2012, the Company owed Immunoclin, Ltd. (“Immunoclin”) $80,389 representing the balance of invoices for clinical services. The Company issued an $80,000 note payable at 8% to Immunoclin in exchange for the outstanding accounts payable. $20,000, $40,000 and $20,000 of the debt were assigned to Coventry Enterprises, LLC (“Coventry”) on December 20, 2012, January 7, 2013, and March 13, 2013, respectively. Coventry made the first conversion of 2,565,102 shares of Company’s common stock to satisfy the debt of $20,000 on December 20, 2012. The Company issued two Convertible Redeemable Notes for the remaining amount of $40,000 and $20,000 on January 7, 2013, and March 13, 2013. Coventry made the conversion of a total of 15,119,481 shares of the company’s restricted stock satisfying the remaining notes in full during the year ended December 31, 2013.  The Company elected to account for these hybrid contracts under the guidance of FASB ASC Topic 815 Derivatives & Hedging.  The fair value has been defined as the common stock equivalent value, enhanced by the fair value of the default put plus the present value of the coupon. The Company recorded a loss of $65,039 on the settlement and the change in fair value of derivatives in the amount of $4,885 during the year ended December 31, 2013.
	During August and September, 2013, the Company issued 3,000,000 shares of the company’s restricted stock to settle the outstanding accounts payable in aggregate of $38,528 with two vendors. The shares were valued at $0.018 per share. The Company recorded a total loss of $15,472 on the settlement date (See Note 7).
	During September, 2013, the Company issued 25,000,000 shares of the company’s restricted stock and 25,000,000 warrants to purchase stock at an exercise price of $0.030 to settle the outstanding accounts payable of $112,621 with one vendor. The shares were valued at $0.015 per share (See Note 7). The Company classified embedded conversion features in the warrants as a derivative liability. The warrants were valued at their fair value of $243,146 and $63,297, respectively using the Black-Scholes method at the commitment and re-measurement dates of September 16, 2013 and December 31, 2013, respectively. The Company recorded a loss of $505,525 on the settlement date (See Note 7).
	During September, 2013, Mr. Harold H. Rumph (ReceptoPharm’s CEO) accepted 14,800,000 shares of the Company’s restricted common stock as a repayment to discharge $37,000 of his accrued salary to the Company (See Note 7).
	During June, August and October 2014, the Company issued a total of 180,000,000 shares of the company’s restricted stock to settle the outstanding commissions’ payable in aggregate of $300,000 with TCN. The shares were valued at a range from $0.0056 to $0.0099 per share. The Company recorded a loss of $1,164,000 as a selling expense during the year ended December 31, 2014(See Note 7).

DUE_TO_OFFICERS

DUE TO OFFICERS	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
DUE TO OFFICERS	5. DUE TO OFFICERS
	At December 31, 2014 and December 31, 2013, the balance due to officers consisted of the following:
			31-Dec-14		December 31,
					2013
	An unsecured demand loan from our President and CEO, Rik Deitsch. The loan bears interest at 4%. The loan balance at December 31, 2014 and 2013, respectively, includes accrued interest payable of $369,983 and $349,466.	$	411,411	$	566,399
	A loan from Paul Reid, the former President of ReceptoPharm bearing interest at a rate of 5% per annum, due on demand and secured by certain intellectual property of ReceptoPharm  having a zero cost at December 31, 2014 and 2013. The accrued interest at December 31, 2014 and 2013 was $49,638 and $43,363, respectively.		129,466		123,189
	Ending balances	$	540,877	$	689,588
	During the year ended December 31, 2014, we borrowed $86,464 and repaid $161,969 to Mr. Deitsch. In addition, Mr. Deitsch accepted a total of 50,000,000 shares of the Company’s restricted common stock as a repayment to discharge $100,000 of his outstanding loan on April 10, 2014(See Note 7).
	During the year ended December 31, 2013, we borrowed $151,718 and repaid $53,600 to Mr. Deitsch. In addition, Mr. Deitsch accepted a total of 50,000,000 shares of the Company’s restricted common stock as a repayment to discharge $162,500 of his outstanding loan to the Company in year ended December 31, 2013(See Note 7).
	During June, 2013, 25,000,000 warrants to purchase stock at an exercise price of $0.10 per share were issued to CEO, Mr. Deitsch in exchange of notes payable. The warrants expired on December 31, 2014 (See Note 8).

OTHER_DEBT

OTHER DEBT	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
OTHER DEBT	6. OTHER DEBT
	Other debt (Both short-term and long term) consists of the following at December 31, 2014 and 2013:
			2014		2013
	Note payable – Related Party   (1)	$	120,000	$	180,000
	Notes payable – Non Related Parties  (2)		540,644		412,182
	Convertible notes payable, at fair value (3)		330,277		767,056
	Ending balances	$	990,921	$	1,359,238
	-1
	During 2010 we borrowed $200,000 from one of our directors. We repaid $60,000 during 2014. Under the terms of the loan agreement, this loan was expected to be repaid in nine months to a year from the date of the loan along with interest calculated at 10% for the first month plus 12% after 30 days from funding. We are in default regarding this loan. At December 31, 2014 and 2013, we owed this director accrued interest of $157,128 and $121,137, respectively.
	(2)At December 31, 2014 and 2013, the balance of $540,644 and $412,182 , respectively, consisted of the following loans:
	·In August 2014, the Company issued a promissory note to the Michael McDonald Trust in the amount of $75,000 bearing monthly interest at a rate of 2%. The note is due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, the Company issued 2,000,000 shares of the Company's common stocks (See note 7). The Company has recorded a debt discount in the amount of $15,665 to reflect the value of the common stocks as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stocks and additional paid-in capital. The total discount of $15,665 was amortized over the term of the debt.  Amortization for the year ended December 31, 2014 was $13,054. In the event of default, the Company will issue an additional 1,000,000 share of the Company’s common stocks on the date that is ten days after the maturity date (See Note 7).
	·In July 2013, the Company issued a promissory note to the Michael McDonald Trust in the amount of $75,000 bearing interest at a rate of 2% per month. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, the Company issued 1,000,000 shares of the Company's common stock. The Company has recorded a debt discount in the amount of $3,977 to reflect the value of the common stocks as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stocks and additional paid-in capital. The total discount of $3,977 was fully amortized over the term of the debt at December 31, 2013. An additional 1,000,000 shares were issued in January 2014 with a fair value at $9,900 (See Note 7) due to the default.  At June 12, 2014, we owed Michael McDonald approximately $92,310, which was assigned and sold to Coventry in the form of a Convertible Redeemable Note (See Note 6(3) and Note 7).
	·On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), the Company agreed to pay LPR a total of $350,000 in monthly installments of $50,000 beginning August 15, 2011 and ending on February 15, 2012. This settlement amount was recorded as general and administrative expenses on the date of the settlement. We did not make the December 2011 or January 2012 payments and on January 26, 2012, we signed the first amendment to the settlement agreement where under we agreed to pay $175,000 which was the balance outstanding at December 31, 2011(this includes a $25,000 penalty for non-payment). The Company repaid $25,000 during the three months ended March 31, 2012. The Company did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell 5,714,326 shares of the Company’s free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 (the initial $350,000 plus total default penalties of $100,000).  The $100,000 default was expensed during 2012.  LPR sold the note to Southridge Partners, LLP (“Southridge”) for consideration of $281,772 in October 2012. The debt has reverted back to the Company (See Note 7).
	·As of December 31, 2014, the Company owed University Centre West Ltd. approximately $55,410, which was assigned and sold to Southridge and subsequently reverted back to the Company.
	·On November 5, 2014, the Company received a loan for a total of $150,000 from a non-related party. The loan is expected to be repaid through scheduled payments through November 13, 2015 along with interest on average 15% annum. The Company has recorded loan costs in the amount of $14,350 for the loan origination fees paid at inception date. The total loan cost of $14,350 was amortized over the term of the loan.  Amortization for the year ended December 31, 2014 was $2,200.  During 2014, repayment of $18,926 was made. At December 31, 2014, the principal balance of the loans is $131,072. The interest expense for the year ended December 31, 2014 is $5,862.
	(3)At December 31, 2014 and 2013, the balance of $330,277 and $767,056 consisted of the following convertible loans:
	·In September and October 2011, the Company borrowed $250,000 each (aggregating $500,000) from two non-related parties.  The principal of these loans were to be repaid with a balloon payment on or before October 1, 2012. On October 19, 2012 the parties amended the notes to extend the due date to May 1, 2013 and include a conversion feature that would allow the holders to convert some or all of their outstanding notes into restricted Company stock at a 15% discount to the average closing market price of the Company's stock traded over the previous 10 days. Interest on these loans is payable monthly beginning in November 2011 with interest calculated at 20% and 12%, each, respectively. At December 31, 2014 and 2013, the accrued interest payable was $4,163 and $6,664, respectively.
	During year ended December 31, 2013 and 2014, the Company issued a total of 34,254,004 shares and 33,226,382 shares of the company’s restricted stock satisfying principal of the notes in the amounts of $125,000 and $92,000, respectively.  The fair value of the shares issued were $317,391 and $177,093 on the dates of conversion.
	During year ended 2013 and 2014, $150,000 and $33,000 of the debts were assigned to three non-related parties in the form of a Convertible Redeemable Note bearing interest of 8% annum with a conversion price for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 to 20 trading days immediately preceding the Conversion Date. Following the assignments, the conversions for a total of 64,052,862 shares and 9,600,000 shares of the company’s restricted stock were made at the fair value of $475,519 and $65,982 (See Note 7). With the above conversions, at December 31, 2014, one of the Notes was satisfied in full and the remaining balance of the other Note was $100,000 with a fair value of $125,980 at December 31, 2014 and matured on February 3, 2015.  On August 3, 2014 and April 30, 2014, the Company issued 1,000,000 and 500,000 restricted shares, respectively, to each note holder in connection with the amendment of maturity date at a fair value of $9,100 and $1,950, respectively (See note 7). On February 1, 2015, the Company issued 1,000,000 restricted shares note holder in connection with the amendment of maturity date to August 3, 2015 (See note 11).
	·On July 10, 2013, the Company issued a Convertible Debentures in the amount of $30,000 to Christopher Castaldo in connection with the agreement for investor relation services. The note carries interest at 8% and is due on January 10, 2014. The note’s holder has the right to convert the note and accrued interest into shares of Common Stock at a price of $0.005. The Company continued to accrue the interest at 8% after the note was in default. On February 26, 2014, the conversion for a total of 6,000,000 shares of the company’s restricted stock was made in satisfying the note in full with a fair value of $51,060 (See Note 7).
	·On October 10, 2013, the Company issued a Convertible Debentures in the amount of $30,000 to Christopher Castaldo in connection with the agreement for investor relation services. The note carries interest at 8% and is due on April 10, 2014. The note’s holder has the right to convert the note into shares of Common Stock at a price of $0.005. The Company continued to accrue the interest at 8% after the note was in default. On April 15, 2014, the conversion for a total of 6,000,000 shares of the company’s restricted stock was made in satisfying the note in full with a fair value of $28,107 (See Note 7).
	·On June 2, 2014, the Company issued a Convertible Debenture in the amount of $10,000 to Christopher Castaldo in connection with an agreement for investor relation services (See Note 7). The note carries interest at 8% and is due on December 2, 2014. The note holder has the right to convert the note, until it is no longer outstanding into shares of Common Stock at a price of $.0035. On December 2, 2014, the conversion for a total of 2,857,143 shares of the company’s restricted stock was made in satisfying the note in full with a fair value of $14,286 (See Note 7).
	·On July 8, 2014, the Company issued a Convertible Debenture in the amount of $10,000 to Christopher Castaldo in connection with an agreement for investor relation services (See Note 6). The note carries interest at 8% and is due on January 8, 2015. The note holder has the right to convert the note, until it is no longer outstanding into shares of Common Stock at a price of $.0035. On January 8, 2015, the conversion for a total of 2,857,143 shares of the company’s restricted stock was made in satisfying the note in full with a fair value of $17,728 (See Note 11).
	In connection with the issuance of this convertible note payable, the Company encountered a day-one derivative loss of $16,361. At December 31, 2014, this convertible note payable, at fair value, was recorded at $16,303.
	·On September 3, 2013, the Company issued a Convertible Debenture in the amount of $100,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 10% and is due on September 3, 2014, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding  into shares of Common Stock at a price lesser of $.018, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company’s Common Stock for the twenty trading days preceding  the conversion date. On March 11, 2014 and June 12, 2014, Coventry made a conversion of a total of 23,376,623 shares and 6,710,121 shares of the company’s restricted stock satisfying $90,000 and $10,000 of the notes in full with a fair value of $187,119 and $65,402, respectively (See note 7).
	In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of 20,000,000 shares of the Company’s common stock at an exercise price of $0.025 per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $87,518 using the Black-Scholes method at December 31, 2014.
	·On September 12, 2013, the Company issued a Convertible Debenture in the amount of $70,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 10% and is due on September 12, 2014, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding  into shares of Common Stock at a price lesser of $.02, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company’s Common Stock for the twenty trading days preceding  the conversion date. On March 12, 2014 and June 12, 2014, Coventry made a conversion of a total of 15,584,415 and 5,789,473 shares of the company’s restricted stock satisfying $60,000 and $10,000 of the notes with a fair value of $123,641 and $60,296, respectively (See note 7).
	In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of 15,000,000 shares of the Company’s common stock at an exercise price of $0.025 per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $65,836 using the Black-Scholes method at December 31, 2014.
	·On April 9, 2014, the Company issued a Convertible Debenture in the amount of $20,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 10% and is due on April 9, 2015, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding  into shares of Common Stock at a price lesser of $.02, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company’s Common Stock for the twenty trading days preceding  the conversion date. . In connection with the issuance of the convertible note payable, the Company encountered a day-one derivative loss of $16,172. At December 31, 2014, the convertible note payable, at fair value, was recorded at $40,627.
	In connection with the issuance of the Note, the Company also granted five-year warrants to purchase an aggregate of 4,000,000 shares of the Company’s common stock at an exercise price of $0.025 per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $18,672 using the Black-Scholes method at December 31, 2014.
	·During June 2014, $92,310 of Michael McDonald’s debt was assigned and sold to Coventry in the form of a Convertible Redeemable Note. The note carries interest at 8% and is due on June 18, 2015, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding  into shares of Common Stock at fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company’s Common Stock for the fifteen trading days preceding  the conversion date. In connection with the issuance of the convertible note payable, the Company encountered a day-one derivative loss of $371,772. On June 18, 2014 and July 2, 2014, Coventry made a conversion of 8,791,389 and 4,293,467 shares of the company’s restricted stock satisfying $18,462 each (total $36,924) of the note with a fair value of $92,816 and $29,909, respectively. At December 31, 2014, the remaining balance of $55,386, at fair value, was recorded at $110,159 (See Note 5(2) and Note 6).
	·On October 7, 2013, the Company signed a secured convertible Promissory Note in the amount of $35,000 in favor of Southridge Partners II, LLC. The note was due on demand and carries interest at 10% annum. Southridge Partners II, LLC was entitled to convert the principal into shares of common stock  at the lesser of $0.015 or a 50% discount from the lowest closing bid price in the 30 trading days prior to the day that the conversion is requested; and interest accrued  was entitled to convert into shares of common stock at $0.001. In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable. At September 30, 2014, this convertible note payable, at fair value, was recorded at $79,663. Southridge converted the note in full for a total of 13,349,057 shares of the company’s restricted stock on April 7, 2014 . Pursuant to the “reset provision” on the note agreement, an additional 2,373,166 shares of common stocks were issued due to stock price depreciation on the clearing date of April 23, 2014. These shares were valued at fair value of $10,679 and recorded as loss on settlement of debt (See note 7).
	On March 19, 2014, the Company issued two Convertible Debentures in the amount of up to $500,000 each (total $1,000,000) to two non-related parties. During the year ended December 31, 2014, the Company recorded the first tranche of $15,000 each (total $30,000) of the funds was received during the first quarter of 2014.  The notes carry interest at 8% and are due on the date that is two years from the execution and funding of the note.  The note holders have the right to convert the notes into shares of Common Stock at a price of $0.005. In connection with the issuance of these convertible notes payable, the Company encountered a day-one derivative loss of $18,104. At December 31, 2014, these convertible notes payable, at fair value, was recorded at $36,450.
	In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable.
	The Company elected to account for these hybrid contracts under the guidance of ASC 815-15-25-4.  The fair value has been defined as the common stock equivalent value, enhanced by the fair value of the default put plus the present value of the coupon.
	The holder of this convertible note has substantial rights and protections regarding dilution if certain events, including a default were to occur. There are a number of events that could trigger a default, including but not limited to failure to pay principal or interest, failure to issue shares under the conversion feature, breach of covenants, breach of representations and warranties, appointment of a receiver or trustee, judgments, bankruptcy, delisting of common stock, failure to comply with the exchange act, liquidation, cessation of operations, failure to maintain assets, material financial statement restatement, reverse split of borrowers stock, etc. In the event of these events the lender may be entitled to receive significant amounts of additional stock above the amounts for conversion.
	Furthermore, there are additional events that could cause the lender to be due additional shares of common stock above and beyond the shares due from a conversion. Some of these events include, but are not limited to a merger or consolidation of the Company, dividend distribution or spin off, dilutive issuances of the Company’s stock, etc. If the lender receives additional shares of the Company’s commons stock due to any of the foregoing events or for other reasons, then this may have an extremely dilutive effect on the shareholders of the Company. Such dilution would likely result in a significant drop in the per share price of the Company’s common stock. The potential dilutive nature of this note presents a very high degree of risk to the Company and its shareholders.

STOCKHOLDERS_DEFICIT

STOCKHOLDERS' DEFICIT	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
STOCKHOLDERS' DEFICIT	7. STOCKHOLDERS' DEFICIT
	Private Placements of Common Stock
	In January 2014, the Company sold 12,000,000 shares of restricted common stock to an investor at a price per share of $0.005 and received proceeds of $60,000. The Company issued 12,000,000 warrants to purchase common stock at an exercise price of $0.03 per share. The warrants expire on December 31, 2015(See Note 8).
	In 2013, the Company sold 10,000,000 shares of restricted common stock to an investor at a price per share of $0.005 and received proceeds of $50,000. The Company issued 10,000,000 warrants to purchase common stock at an exercise price of $0.03 per share. The warrants expire on December 31, 2015.
	In 2013, the Company sold an aggregate of 11,000,000 shares of restricted common stock to five investors at a price per share range from $0.002 to $0.015 and received proceeds of $45,000. The Company issued a total of 1,000,000 warrants to purchase common stock at an exercise price of $0.10 per share. The warrants expire on December 31, 2014.
	In 2013, the Company sold an aggregate of 21,000,000 shares of restricted common stock to two investors at a price per share range from $0.001 to $0.0042 and received proceeds of $45,000.
	Shares Issued to Employees and Directors
	During December 2014, the Board of Directors approved a resolution for the issuance of a total of 54,092,000 shares of the Company’s restricted common stock to directors and employees of the Company. The issuance was valued at $324,552 ($0.006 per share), which was the fair value of the Company’s common stock on the date of issuance.
	On November 22, 2013, the Board of Directors approved a resolution for the issuance of a total of 34,630,000 shares of the Company’s restricted common stock to directors and employees of the Company. The issuance was valued at $484,820 ($0.014 per share), which was the fair value of the Company’s common stock on the date of issuance.
	On September 3, 2013, the Board of Directors approved a resolution for the issuance of 1,000,000 shares of the Company’s restricted common stock to an employee of the Company. The issuance was valued at $22,900 ($0.0229 per share), which was the fair value of the Company’s common stock on the date of issuance.
	Common Stock Issued for Services
	During December 2014, the Company issued 3,775,000 shares of the Company’s restricted common stock to sales representatives for services rendered with a fair value of $26,048. The share was valued at $0.0069 per share.
	During December 2014, the Company issued 2,000,000 shares of the Company’s restricted common stock to a consultant for services rendered with a fair value of $12,000. The share was valued at $0.006 per share.
	During November 2014, the Company issued 2,000,000 shares of the Company’s restricted common stock to a consultant for services for one year. The share was valued at $0.008 per share. The Company recorded an equity compensation charge of $1,929 during the year ended December 31, 2014. The remaining unrecognized compensation cost of $14,071 related to non-vested equity-based compensation to be recognized by the Company over the remaining vesting period of ten and half months.
	During November 2014, the Company issued 5,000,000 shares of the Company’s restricted common stock to a consultant for services for one year. The share was valued at $0.0072 per share. The Company recorded an equity compensation charge of $5,918 during the year ended December 31, 2014. The remaining unrecognized compensation cost of $30,082 related to non-vested equity-based compensation to be recognized by the Company over the remaining vesting period of ten months.
	During July 2014, the Company signed an agreement with a consultant for investor relation services for seven weeks. In connection with the agreement, 5,000,000 shares of company’s restricted common stocks were issued with a fair value of $45,500. A $10,000 convertible note convertible at $0.0035 per share was also issued (See Note 6).
	During May 2014, the Company signed an agreement with a consultant for investor relation services for one month. In connection with the agreement, 5,000,000 shares of company’s restricted common stocks were issued with a fair value of $18,500. A $10,000 convertible note convertible at $0.0035 per share was also issued (See Note 6).
	During June 2014, the Company issued 5,000,000 shares of the Company’s restricted common stock to a consultant for services for one year. The share was valued at $0.0085 per share. The Company recorded an equity compensation charge of $22,938 during the year ended December 31, 2014. The remaining unrecognized compensation cost of $19,562 related to non-vested equity-based compensation to be recognized by the Company over the remaining vesting period of five and half months.
	During August, 2013, the Company issued a total of 6,000,000 shares of the Company’s restricted common stock to two consultants for investor relation services for six months. The shares were valued at $0.0173 per share. The Company recorded an equity compensation charge of $70,902 during the four months ended December 31, 2013, and the remaining compensation cost of $32,899 was recognized by the Company during the year ended December 31, 2014.
	During August, 2013, the Company issued 2,000,000 shares of the Company’s restricted common stock to a consultant for investor relation services for one year. The shares were valued at $0.012 per share. The Company recorded an equity compensation charge of $8,351 during the four months ended December 31, 2013 and the remaining compensation cost of $15,649 was recognized by the Company during the year ended December 31, 2014.
	During August, 2013, the Company issued 2,000,000 shares of the Company’s restricted common stock to a consultant for consulting services for six months. The shares were valued at $0.0056 per share. The Company recorded an equity compensation charge of $8,446 during the four and one half months ended December 31, 2013, and the remaining compensation cost of $2,754 was recognized by the Company during the year ended December 31, 2014.
	During February, 2013, the Company issued 8,000,000 shares of the Company’s restricted common stock to a consultant for investor relation services for a year. The shares were valued at $0.008 per share. The Company recorded an equity compensation charge of $61,019 during the year ended December 31, 2013. The remaining compensation cost of $2,981 was recognized by the Company during the year ended December 31, 2014.
	During November, 2013, the Company issued 1,000,000 shares of the Company’s restricted common stock to a consultant for investor relation services for two months. The shares were valued at $0.0175 per share. The Company recorded an equity compensation charge of $17,500 during the year ended December 31, 2013.
	During October, 2013, the Company issued 15,000,000 shares of the Company’s restricted common stock to a consultant for investor relation services for three months. The shares were valued at $0.0178 per share. The Company recorded an equity compensation charge of $267,000 during the year ended December 31, 2013.
	During September, 2013, the Company issued 1,500,000 shares of the Company’s restricted common stock to a consultant for consulting services rendered. The shares were valued at $0.016 per share. The Company recorded an equity compensation charge of $24,000 during the year ended December 31, 2013.
	During September, 2013, the Company issued a total of 1,500,000 shares of the Company’s restricted common stock to two consultants for consulting services rendered. The shares were valued at $0.0229 per share. The Company recorded an equity compensation charge of $34,350 during the year ended December 31, 2013.
	During July, 2013, the Company issued 2,000,000 shares of the Company’s restricted common stock to a consultant for consulting services for six months. The shares were valued at $0.0042 per share. The Company recorded an equity compensation charge of $8,400 during the year ended December 31, 2013.
	During July, 2013, the Company issued 100,000 shares of the Company’s restricted common stock to a consultant for consulting services rendered. The shares were valued at $0.0042 per share. The Company recorded an equity compensation charge of $420 during the year ended December 31, 2013
	During July 2013, the Company signed an agreement with a consultant for investor relation services for three months. A $30,000 convertible note convertible at $0.005 per share was also issued (See Note 6). The Company also paid a total of $10,000 cash and issued a total of 15,000,000 shares of company’s restricted common stocks. The shares were valued at $0.0057 per share. The Company recorded an equity compensation charge of $85,500 during the year ended December 31, 2013.
	During June, 2013, the Company issued 2,000,000 shares of the Company’s restricted common stock to a consultant for investor relation services for six months. The shares were valued at $0.0042 per share. The Company recorded an equity compensation charge of $8,400 during the year ended December 31, 2013.
	During May, 2013, the Company issued 1,000,000 shares of the Company’s restricted common stock to a consultant for investor relation services for six months. The shares were valued at $0.0053 per share. The Company recorded an equity compensation charge of $5,300 in May 2013.
	During February 2013, the Company issued 1,500,000 shares of the Company’s restricted common stock to a consultant for investor relation services for two months. The shares were valued at $0.007 per share. The Company recorded an equity compensation charge of $10,500 during the year ended December 31, 2013.
	During February 2013, the Company issued a total of 3,000,000 shares of the Company’s restricted common stock to three consultants for marketing services for six months. The shares were valued at $0.009 per share. The Company recorded an equity compensation charge of $27,000 during the year ended December 31, 2013.
	During January, 2013, the Company issued 10,000,000 shares of the Company’s restricted common stock to a consultant for investor relation services for a year. The shares were valued at $0.005 per share. The Company recorded an equity compensation charge of $50,000 during the year ended December 31, 2013.
	On December 14, 2012 the Company issued a total of 1,000,000 shares of the Company’s restricted common stock to Roetzell & Andress for legal services for a one year term. The shares were valued at $0.014 per share. The Company recorded a prepaid equity compensation charge of $14,000 during the year ended December 31, 2012, and recognized an equity compensation charge of $14,000 during the year ended December 31, 2013.
	During October, 2012 the Company issued a total of 15,100,000 shares of the Company’s restricted common stock to five consultants for marketing services for six months terms. The shares were valued at $0.0125 per share. The Company recorded an equity compensation charge of $108,534 and $80,216 during the year ended December 31, 2013 and year ended December 31, 2012.
	During December, 2012 the Company issued 500,000 shares of the Company’s restricted common stock to a consultant for real estate consulting services for a six months term. The shares were valued at $0.0125 per share. The Company recorded an equity compensation charge of $1,042 during the year ended December 31, 2012. The remaining unrecognized compensation cost of $5,208 was recognized during the year ended December 31, 2013.
	During August, 2012 the Company issued 3,000,000 shares of the Company’s restricted common stock to JPU Ventures, Inc. under agreement dated August 13, 2012. The agreement was for investor relations services for a nine months term. The shares were valued at $0.0125 per share. The Company recorded an equity compensation charge of $21,875 during the year ended December 31, 2012. The remaining unrecognized compensation cost of $15,625 was recognized by the Company during the year ended December 31, 2013.
	On October 1, 2012, the Company issued 5,500,000 shares of the Company’s restricted common stock under the amended agreement with Mark Bergman, a consultant. The contract is for six months term. The shares were valued at $0.0125 per share. The Company recorded an equity compensation charge of $28,646 and $40,104 for the agreement during the year ended December 31, 2013 and the year ended December 31, 2012.
	During October, 2012, the Company entered into an agreement for investor relations services with a Consultant. The contract was for a six months term and calls for the issuance of 1,000,000 shares of restricted common stock. The share was valued at $0.0125 per share. The Company recorded an equity compensation charge of $8,697 during the year ended December 31, 2012. The remaining unrecognized compensation cost of $3,533 was recognized by the Company during the year ended December 31, 2013.
	On February 22, 2012 the Company engaged Capital Path Securities, LLC (“CPS”) as its exclusive advisor on a proposed placement by way of an equity line of approximately $10,000,000 of the Company’s equity or equity linked securities. All upfront fees have been waived by CPS. The Company will pay CPS a cash placement fee equal to 5% of all principal amounts invested from the source originated by CPS. In addition, 10,000,000 restricted shares were issued on October 26, 2012, and valued at $0.0125 per share. The Company recorded an equity compensation charge of $151,375 during the year ended December 31, 2012. The remaining unrecognized compensation cost of $21,625 and 125,000 non-vested shares was recognized by the Company during the year ended December 31, 2013.
	Common Stock Issued for Debt Modification
	On January 17, 2014, the Company issued a total of 1,000,000 restricted shares to the Michael McDonald Trust due to the default on repayment of the promissory note of $75,000. The shares were valued at a fair value of $9,900.
	On April 30, 2014, the Company amended the maturity dates of notes $75,000 from a non-related party to November 3, 2014. The Company issued a total of 500,000 restricted shares to the note holder per the amendment. The shares were valued at a fair value of $1,950 (See note 6).
	On August 1, 2014, the Company amended the maturity dates of notes $100,000 from a non-related party to February 3, 2015. The Company issued a total of 1,000,000 restricted shares to the note holder per the amendment. The shares were valued at a fair value of $9,100 (See note 6).
	On April 30, 2013, the Company amended the maturity dates of two notes of $250,000 each (aggregating $500,000) from two non-related parties to November 3, 2013. The Company issued a total of 4,000,000 restricted shares to the note holders in connection with the amendment at a fair value of $20,800(See note 6).
	On October 30, 2013 and November 1, 2013, the parties amended the note of $75,000 and $150,000 to further extend the maturity dates to May 3, 2014 and August 3, 2014. The Company issued a total of 500,000 and 1,250,000 restricted shares to the note holders in connection with the amendment at a fair value of $9,500 and $13,750, respectively (See Note 6).
	Common Stock Issued with Promissory Note
	In August 2014, in connection with the issuance of this promissory note to Michael McDonald Trust in the amount of $75,000 which is due in six months from the funding of the note, the Company issued 2,000,000 shares of the Company's common stocks. The Company has recorded a debt discount in the amount of $15,665 to reflect the value of the common stocks as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stocks and additional paid-in capital. The total discount of $15,665 was amortized over the term of the debt.  Amortization for the year ended December 31, 2014 was $13,054 (See Note 6).
	In July 2013, in connection with the issuance of this promissory note to Michael McDonald Trust in the amount of $75,000 which is due in six months from the funding of the note, the Company issued 1,000,000 shares of the Company's common stocks. The Company has recorded a debt discount in the amount of $3,977 to reflect the value of the common stocks as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stocks and additional paid-in capital. The total discount of $3,977 was amortized over the term of the debt.  Amortization for the year ended December 31, 2013 was $3,977 (See Note 6).
	Common Stock Held in Escrow
	On July 27, 2011 the Company issued 5,714,286 shares of free trading common stock in certificate form which is held in escrow as security under an agreement reached with Liquid Packaging Resources, Inc.  (“LPR”) on August 2, 2011(See Note 4 and 6).
	Common Stock Issued for Settlement of Accounts Payable & Debt
	Following the agreements with Castaldo for $10,000 in June 2014, Castaldo made the conversion for a total of 2,857,143 shares of the company’s restricted stock satisfying the notes in full with a fair value of $14,286 during December 2014 (See Note 6).
	Following the agreements with Castaldo for $30,000 each (total $60,000) in July 2013 and October 2013, Castaldo made the conversion for a total of 12,000,000 shares of the company’s restricted stock satisfying the notes in full with a fair value of $79,167 during February and April 2014 (See Note 6).
	Following the agreement with Southridge Partners II, LLC for $35,000 in October 2013, Southridge converted the note in full for a total of 13,349,057 shares of the Company’s restricted stock on April 7, 2014.Pursuant to the “reset provision” on the note agreement, an additional 2,373,166 shares of common stocks were issued due to stock price depreciation on the clearing date of April 23, 2014. These shares were valued at a fair value of $10,679 and recorded as loss on settlement of debt (See Note 6).
	Following the assignment of Michael McDonald’s debt of $92,310 in June 2014, Coventry made the following conversions of a total of 13,084,856 shares of the company’s restricted stock satisfying $36,924 of the note with a fair value of $122,725 (See Note 6).
	Date	Number of		Fair Value of
		shares converted		Debt Converted
	6/18/14	8,781,389	$	92,816
	7/2/14	4,293,467	$	29,909
	During June, August and October 2014, the Company issued a total of 180,000,000 shares of the company’s restricted stock to settle the outstanding commissions’ payable in aggregate of $300,000 with TCN. The shares were valued at a range from $0.0056 to $0.0099 per share. The Company recorded a loss of $1,164,000 as a selling expense during the year ended December 31, 2014(See Note 4).
	During May and June, 2014, the two convertible Notes holders made the following conversions of a total of 33,226,382 shares of the company’s restricted stock satisfying the notes in the amount of $92,000 with a fair value of $177,093 on the dates of conversions (See Note 6).
	Date	Number of		Fair Value of
shares converted		Debt Converted
5/30/14	23,529,412	$	79,632
6/16/14	4,545,455	$	45,820
6/14/14	5,151,515	$	51,641
During February and June, 2014, $23,000 and $10,000 of the convertible notes were assigned to third parties with a conversion price at $0.005 and $0.002 per share, respectively. The conversions for a total of 9,600,000 shares of the company’s restricted stock were made as followings in satisfying the notes of $33,000 at the fair value of $65,982 (See Note 6).
Date	Number of		Fair Value of
	shares converted		Debt Converted
2/10/14	4,600,000	$	30,726
6/14/14	5,000,000	$	35,256
Following the agreements with Coventry Enterprises, LLC (see Note 6) for $100,000 and $70,000 in September 2013, Coventry made the following conversions for a total of 51,460,632 shares of the company’s restricted stock during the year ended December 31, 2014 satisfying the Notes in full (See note 6):
Date	Number of		Fair Value of
	shares converted		Debt Converted
3/11/14	23,376,623	$	187,119
3/12/14	15,584,415	$	123,641
6/12/14	12,499,594	$	103,142
On April 10, 2014, Mr. Deitsch accepted a total of 50,000,000 shares of the Company’s restricted common stock as a repayment to discharge $100,000 of his outstanding loan to the Company (See note 5). The shares were valued at the note payable amount due to the fact that it was a related party transaction.
Following the agreements with Coventry Enterprises, LLC (see Note 6) for $80,000, Coventry made the following conversions for a total of 15,119,481 shares of the company’s restricted stock during the first quarter of 2013 satisfying the notes in full and recorded a loss of $65,039 (See Note 6):
Date	Number of		Fair Value of
	shares converted		Debt Converted
1/21/13	4,032,258	$	37,619
2/11/13	5,405,405	$	42,510
3/20/13	5,681,818	$	40,414
Following the agreement with Coventry Enterprises, LLC (see Note 6) for $88,500, Coventry made the following conversions for a total of 31,416,845 shares of the company’s restricted stock during the second quarter of 2013 satisfying the notes in full:
Date	Number of		Fair Value of
	shares converted		Debt Converted
4/17/13	7,133,333	$	49,586
5/16/13	11,101,694	$	64,930
6/12/13	13,181,818	$	70,130
Following the agreement with Coventry Enterprises, LLC (see Note 6) for $60,000, Coventry made the conversion for a total of 27,272,727 shares of the company’s restricted stock during the second quarter of 2013 satisfying the notes in full with a fair value of $167,495. The Company recorded a loss of $2,200 (See note 6).
Following the agreement with Coventry Enterprises, LLC (see Note 6) for $20,000, Coventry made the conversion for a total of 8,810,572 shares of the company’s restricted stock during September 2013 satisfying the notes in full with a fair value of $188,747.
During June and August, 2013, one of the convertible Notes holders made the following conversions of a total of 34,254,004 shares of the company’s restricted stock satisfying the notes in the amount of $125,000 with a fair value of $317,391 on the date of conversion (See Note 6).
Date	Number of		Fair Value of
	shares converted		Debt Converted
6/25/13	22,058,882	$	188,352
8/30/13	12,195,122	$	129,039
During August and September, 2013, $150,000 of the convertible notes were assigned to third parties in the form bearing interest of 8% annum at with a conversion price for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 to 20 trading days immediately preceding the Conversion Date. Immediately following the assignments, the conversions for a total of 64,052,862 shares of the company’s restricted stock were made as followings in satisfying the notes of $150,000 at the fair value of $475,519(See Note 6).
Date	Number of		Fair Value of
	shares converted		Debt Converted
8/28/13	22,026,431	$	167,493
9/3/13	20,000,000	$	163,909
9/4/13	22,026,431	$	144,117
On September 16, 2013, one of the non-related party promissory note holders accepted a total of 8,472,750 shares of the Company’s restricted common stock as a repayment to discharge $25,000 of his outstanding loan and accrued interest of $11,120 with the Company (See note 6). The Company recorded a loss of $90,971 on the settlement date.
On November 25, 2013, one of the non-related party promissory note holders accepted a total of 4,360,000 shares of the Company’s restricted common stock as a repayment to discharge $25,000 of his outstanding loan and accrued interest of $11,956 with the Company (See note 6). The Company recorded a loss of $28,444 on the settlement date.
During September, 2013, Mr. Harold H. Rumph (ReceptoPharm’s CEO) accepted 14,800,000 shares of the Company’s restricted common stock as a repayment to discharge $37,000 of his accrued salary to the Company(See Note 4).
During June and September, 2013, Mr. Deitsch (Our CEO) accepted a total of 50,000,000 shares of the Company’s restricted common stock as a repayment to discharge $162,500 of his outstanding loan to the Company (See note 5).
During August and September, 2013, the Company issued 3,000,000 shares of the company’s restricted stock to settle the outstanding accounts payable in aggregate of $38,528 with two vendors. The shares were valued at $0.018 per share. The Company recorded a loss of $15,472 (See Note 4).
During September, 2013, the Company issued 25,000,000 shares of the company’s restricted stock and 25,000,000 warrants to purchase stock at an exercise price of $0.030 to settle the outstanding accounts payable of $112,621. The shares were valued at $0.015 per share. The Company recorded a loss of $505,525(See Note 4).

STOCK_OPTIONS_AND_WARRANTS

STOCK OPTIONS AND WARRANTS	12 Months Ended
	Dec. 31, 2014
Other Liabilities Disclosure [Abstract]
STOCK OPTIONS AND WARRANTS	8. STOCK OPTIONS AND WARRANTS
	Common Stock Warrants
	From time to time, we issue warrants to purchase our common stock. These warrants have been issued for cash in conjunction with the private placement of shares of our common stock.
	During January 2014, the Company issued a total of 12,000,000 warrants to purchase common stock at an exercise price of $0.03 per share in connection with the private placement offerings. The warrants expire on December 31, 2015 (See Note 7).
	During April, 2014, the Company issued a total of 4,000,000 warrants to purchase common stock at an exercise price of $0.025 per share in connection with issuance of a convertible note payable to Coventry. The warrants expire on April 9, 2019 (See Note 7).
	During December 2013, the Company issued a total of 10,000,000 warrants to purchase common stock at an exercise price of $0.03 per share in connection with the private placement offerings. The warrants expire on December 31, 2015 (See Note 7).
	During October and November 2013, the Company issued a total of 1,000,000 warrants to purchase common stock at an exercise price of $0.10 per share in connection with the private placement offerings. The warrants expired on December 31, 2014 (See Note 7).
	On September 16, 2013, the Company issued 25,000,000 warrants to purchase stock at an exercise price of $0.030 in connection with settlement of an outstanding account payable. The warrants expired on December 31, 2014 (See Note 6 and Note 7).
	On September 3, 2013 and September 12, 2013, the Company issued 20,000,000 and 15,000,000 warrants, respectively, to purchase common stock at an exercise price of $0.025 per share in connection with issuances of convertible notes payable to Coventry. The warrants expire on September 3, 2018 and September, 12, 2018, respectively (See Note 7).
	During March, 2013, the Company issued a total of 2,600,000 warrants to purchase common stock at an exercise price of $0.01 per share in connection with issuance of a convertible note payable to Coventry. The warrants expire on March 22, 2018 (See Note 7).
	During June, 2013, 25,000,000 warrants to purchase stock at an exercise price of $0.10 per share were issued to CEO, Mr. Deitsch in exchange of notes payable. The warrants expired on December 31, 2014 (See Note 5).
	In the third quarter 2012, The Company issued a total of 27,000,000 warrants to purchase common stock at an exercise price of $0.10 per share in connection with a private placement offering. The warrants expired on December 31, 2014.
	In the fourth quarter 2012, the Company issued a total of 17,650,000 warrants to purchase common stock at an exercise price of $0.10 per share in connection with the private placement offerings. The warrants expired on December 31, 2014.
	10,000,000 warrants to purchase stock at an exercise price of $0.10 per share were issued to CEO, Mr. Dietsch in December 2012. The warrants expired on December 31, 2014.
	During January 2011, the Company issued a total of 1,000,000 warrants to purchase common stock at an exercise price of $0.10 per share in connection with the private placement offerings. The warrants expired on December 31, 2014.
	A summary of warrants outstanding in conjunction with private placements of common stock were as follows during the year ended December 31, 2014 and 2013:
			Number		Weighted average
			of shares		exercise price
	Balance December 31, 2012		57,256,667	$	0.1
	Exercised		-		-
	Issued		98,600,000	$	0.01 – 0.10
	Forfeited/Expired		-940,000		-
	Balance December 31, 2013		154,916,667	$	0.082
	Exercised		-		-
	Issued		16,000,000	$	0.03
	Forfeited		-106,650,000		-
	Balance December 31, 2014		64,266,667	$	0.081
	The following table summarizes information about fixed-price warrants outstanding as of December 31, 2014 and 2013:
			Exercise		Number	Weighted		Weighted
			Price		Outstanding	Average		Average
						Contractual		Exercise
						Life		Price
	2014	$	0.01-0.03		64,266,667	2.76 years	$	0.081
	2013	$	0.01-0.10		154,916,667	1.97 years	$	0.082
	As of December 31, 2014, the aggregate intrinsic value of all stock options and warrants outstanding and expected to vest was $0. The intrinsic value of each option share is the difference between the fair value of our common stock and the exercise price of such option share to the extent it is “in-the-money”. Aggregate intrinsic value represents the value that would have been received by the holders of in-the-money options had they exercised their options on the last trading day of the year and sold the underlying shares at the closing stock price on such day. The intrinsic value calculation is based on the $0.0057, closing stock price of our common stock on December 31, 2014.There were no in-the-money warrants at December 31, 2014.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
INCOME TAXES	9. INCOME TAXES
	The Company’s tax expense differs from the “expected” tax expense for the years ended December 31, 2014 and 2013, (computed by applying the Federal Corporate tax rate of 34% to loss before taxes and 5.5% for Florida State Corporate Taxes, the blended rate used was 37.63%), are approximately as follows:
			December 31,
			2014		2013
	Computed "expected" tax expense (benefit) - Federal	$	-813,848	$	-1,346,076
	Computed "expected" tax expense (benefit) - State		-139,314		-322,564
	Permeate differences		797,895		1,010,838
	Change in valuation allowance		155,267		657,802
		$	-	$	-
	Current portion of net deferred income tax assets:		2014		2013
	Allowance for doubtful accounts	$	-	$	242,000
	Reserve for inventory obsolescence		-		313,925
	Accrued salary		155,267		101,877
	Subtotal		155,267		657,802
	Valuation allowance		-155,267		-657,802
	Current net deferred income tax asset		-		-
	Non- current portion of net deferred income tax asset
	Net operating loss carryforwards		10,739,524		10,584,257
	Valuation allowance		-10,739,524		-10,584,257
	Non-current net deferred income tax asset	$	-	$	-
	Due to the uncertainty of the utilization and recoverability of the loss carry-forwards and other deferred tax assets, we have provided a valuation allowance to fully reserve such assets.
	As of December 31, 2014, the Company has net operating loss carryforwards of approximately $29,800,000 available to offset future taxable income in various years through December 31, 2034.  The significant difference between such net operating loss carryforwards and our accumulated deficit of approximately $44,520,000 results primarily from stock based compensation and debt settlements which are considered to be permanent differences.
	The valuation allowances increased by approximately $155,000 and $658,000 for the years ended December 31, 2014 and 2013, respectively. The Company’s 2011 to 2014 tax returns are subject to examination by Internal Revenue Services and State Taxing Agency’s.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	10. COMMITMENTS AND CONTINGENCIES
	Operating Leases
	In February 2010, Nutra Pharma entered into an operating lease for the use of office space. The lease expired in January 2013 and required monthly payments of approximately $9,000. In February 2013, Nutra Pharma entered into a new operating lease for monthly payments of approximately $3,500 for three years. ReceptoPharm leases a lab and renewed its operating lease agreement for five years in July of 2012. The lease requires monthly payments of approximately $5,000 beginning August 1, 2012.
	Future minimum payments under these lease agreements, including the extension period, are approximately as follows:
	Years ended December 31,		Amounts
	2015	$	120,218
	2016		79,892
	2017		45,249
	Total	$	245,359
	Rent expense in 2014 and 2013 approximated $119,215 and $114,889, respectively.
	Litigation
	Patricia Meding, et. al. v. ReceptoPharm, Inc. f/k/a Receptogen, Inc.
	On August 18, 2006, ReceptoPharm was named as a defendant in Patricia Meding, et. al. v. ReceptoPharm, Inc. f/k/a Receptogen, Inc., Index No.: 18247/06 (New York Supreme Court, Queens County). The original proceeding claimed that ReceptoPharm owed the Plaintiffs, including Patricia Meding, a former ReceptoPharm officer and shareholder and several corporations that she claims to own, the sum of $118,928.15 plus interest and counsel fees on a series promissory notes that were allegedly executed in 2001 and 2002. On August 23, 2007, the Queens County New York Supreme Court issued a decision denying Plaintiffs motion for summary judgment in lieu of a complaint, concluding that there were issues of fact concerning the enforceability of the promissory notes. On May 23, 2008, the Plaintiffs filed an amended complaint in which they reasserted their original claims and asserted new claims seeking damages of no less than $768,506 on their claims that in or about June 2004 ReceptoPharm breached its fiduciary duty to the Plaintiffs as shareholders of ReceptoPharm by wrongfully canceling certain of their purported ReceptoPharm share certificates. In late 2010, Plaintiffs further amended their complaint alleging that ReceptoPharm violated Plaintiffs contractual and statutory rights by cancelling an additional 1,214,800 share certificates and failing to permit the Plaintiffs to exercise dissenting shareholder rights with respect to those share certificates. The damages associated with the Plaintiff’s claims could rise as the result of increases in our share price as the Receptopharm shares may be convertible into our common shares. The potential exposure may exceed $10,000,000 if the Plaintiffs are successful with all of their claims.
	ReceptoPharm believes the suit is without merit and has filed an answer denying the material allegations of the amended complaint and asserted a series of counterclaims against the Plaintiffs alleging claims for declaratory judgment, fraud, breach of fiduciary duty, conversion and unjust enrichment as a result of the promissory notes. Plaintiffs have moved for partial summary judgment on their claims regarding the additional 1,214,800 shares, but not on their claims regarding the alleged promissory notes or the 1,750,000 alleged shares. In August of 2011, the Plaintiff's motion was partially granted. In September 2012, ReceptoPharm's attorneys filed a Motion to be removed as counsel. On October 10, 2014 their motion was granted. ReceptoPharm is seeking new counsel to oppose the partial summary judgment and represent the Company. We intend to vigorously contest this matter.
	Liquid Packaging Resources, Inc. v. Nutra Pharma Corp. and Erik "Rik" Deitsch
	On April 21, 2011, Nutra Pharma Corp. and its CEO, Erik Deitsch, were named as defendants in Liquid Packaging Resources, Inc. v. Nutra Pharma Corp. and Erik "Rik" Deitsch, Superior Court of Fulton County, Georgia, Civil Action No. 2011-CV-199562. Liquid Packaging Resources, Inc. ("LPR") claimed that Nutra Pharma Corp. and Mr. Deitsch, directly or through other companies, placed orders with LPR that required LPR to purchase components from third parties. LPR sought reimbursement for those third party expenses in the amount of not less than $359,826.85 plus interest. LPR also sought punitive damages in the amount of not less than $500,000 and attorney's fees.
	Mr. Deitsch and Nutra Pharma Corp. then removed the action to the United States District Court, Northern District of Georgia, Civil Action No. 11-CV-01663-ODE. After removal, LPR amended the Complaint to assert that Nutra Pharma Corp. and Mr. Deitsch were the alter egos of the alleged other companies through whom the subject orders were placed and therefore should be considered one and the same. Mr. Deitsch and Nutra Pharma Corp.  moved to dismiss the Complaint on several grounds including statute of frauds, failure to state a claim, and jurisdiction (only for Mr. Deitsch). Mr. Deitsch and Nutra Pharma Corp.  believe the suit is without merit.
	After June 30, 2011, at LPR's request, the parties mediated the dispute before LPR responded to the Motion To Dismiss. At the mediation, the parties worked out an agreement whereby Nutra Pharma Corp.  would purchase from LPR the components LPR purchased from third parties at an amount slightly less than the principal amount of the suit and on terms acceptable to us. The agreed price was $350,000 payable over 7 months in equal $50,000 amounts. This agreement was reached by us because it provided tangible value in exchange for the purchase price rather than incurring the expense of litigation, which would likely be substantial and not recouped. While Nutra Pharma Corp.  had counterclaims we could assert, we believe this was a practical resolution. The settlement allowed us to take possession of the components prior to full payment and, in exchange, provided security to LPR in the form of our stock valued at $400,000 at the time of issuance. The stock can only be sold in event of a default of the payment schedule. The litigation was dismissed in August of 2011. We made the August, September and November payments (totaling $150,000) in a timely fashion. We were late for the payment due October 15, 2011 and requested an accommodation from LPR, eventually paying an extra $5,000 towards that payment. At December 31, 2011, Nutra Pharma Corp. had made total payments of $205,000 with an additional $150,000 owed. In order to allow us to skip the December payment, LPR agreed to another accommodation whereby we would pay both the December and January payment with an additional $10,000 on or before January 16, 2012. We were unable to make this payment and on January 26, 2012 signed an amended payment schedule adding an additional $15,000 for a total of $175,000 owed. Our CEO, Rik Deitsch, added additional collateral stock in a separate company that he held personally. $25,000 was paid in January, with subsequent payments of $30,000 due monthly on the 15th of March through the 15th of July, 2012. We failed to make the March payment and was subsequently called in default of the Agreement. Under the original agreement, if we are in default of the agreement, LPR has the right to sell shares of our free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 representing the new total cash amount due to LPR by the Company.
	On June 11, 2012, LPR sold their debt to Southridge Partners, LLP in an agreement to be paid out over time. In August, 2013, LPR cancelled their agreement with Southridge Partners, LLP.  As of December 31, 2014, LPR continues to hold the collateral stock. We are currently negotiating a settlement with LPR. Upon the settlement of the outstanding debt, LPR will return the collateral shares to the Company.
	Involuntary Petition of Bankruptcy
	On August 31, 2012, certain former ReceptoPharm employees and a former ReceptoPharm consultant filed a Petition for Involuntary Bankruptcy against us in the United States Bankruptcy Court, Southern District of Florida. The Petitioners originally claimed they were owed $990,927 from Nutra Pharma in the form of accrued wages and promissory notes, but amended their claim to $816,662 in a subsequent filing. In response to the Petition, we filed a motion to dismiss the action which, if successful, would avoid the case being converted into an actual bankruptcy action. On September 30, 2013, the Company entered into a Settlement Agreement with the Petitioners, which is effective upon the court dismissal of the action.  In full and final satisfaction of all claims, the Company settled the Agreement with the Petitioners for a total sum of $350,000.  $35,000 has been paid and a second lump sum payment is due within 8 months from February 12, 2014, the date the court dismissed the action.  The Parties executed mutual releases exclusive of releases under the Settlement Agreement. On October 21, 2014 we received a Notice of Default from the Petitioners' counsel. We have responded to the notice and will be seeking remedies to the default.
	Laurence N. Raymond v. Receptopharm, Inc. et al.
	On December 30, 2011 Laurence N. Raymond ("Raymond") brought the case against Receptopharm, Inc. ("Receptopharm") and Nutra Pharma to recover approximately $300,000 that was allegedly either loaned to Receptopharm or owing to Raymond pursuant to an oral employment agreement. Dr. Raymond is one of the petitioning creditors that brought the above-described involuntary bankruptcy action. The settlement agreement reached in that action fully resolves all claims between the parties and specifies that this action will be dismissed immediately upon the full settlement payments, pursuant to a confidential settlement agreement.
	Paul F. Reid v, Harold H. Rumph et al.
	On December 28, 2011 Paul F. Reid ("Reid") brought the case against Harold H. Rumph ("Rumph"), Receptopharm, and Nutra Pharma to recover approximately $330,000 that was allegedly either loaned to Receptopharm or owing to Reid pursuant to an oral employment agreement. Dr. Reid is one of the petitioning creditors that brought the above-described involuntary bankruptcy action. The settlement agreement reached in that action fully resolves all claims between the parties and specifies that this action will be dismissed immediately upon the full settlement payments, pursuant to a confidential settlement agreement.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	11.  SUBSEQUENT EVENTS
	Common Stock Issued for Services
	During January, 2015, the Company signed an agreement with a consultant for investor relation services for a month. In connection with the agreement, 4,000,000 shares of company’s restricted common stocks were issued.
	During January, 2015, the Company signed an agreement with a consultant for investor relation services for six months. In connection with the agreement, 10,000,000 shares of company’s restricted common stocks were issued.
	Common Stock Issued for Debt Modification and Default
	On February 1, 2015, the Company issued 1,000,000 restricted shares note holder in connection with the amendment of maturity date to August 3, 2015 (See note 6).
	Common Stock Issued for Debt Conversions
	During January, 2015, following the assignment of Michael McDonald’s debt of $92,310 in June 2014, Coventry made the final conversion of a total of 18,461,923 shares of the company’s restricted stock satisfying remaining $55,386 of the note in full (See Note 6 and 7).
	During January, 2015, following the agreement with Christopher Castaldo for $10,000 on July 8, 2014, the conversion for a total of 2,857,143 shares of the company’s restricted stock was made in satisfying the note in full (See Note 6).
	During January, 2015, Mr. Deitsch accepted a total of 5,000,000 shares of the Company’s restricted common stock as a repayment to discharge $10,000 of his outstanding loan to the Company (See note 4). The shares were valued at the note payable amount due to the fact that it was a related party transaction.
	Convertible Debts
	On February 25, 2015, the Company issued a Convertible Debenture in the amount of $68,250 to LG Capital Funding, LLC (“LG”). The note carries interest at 9% and is due on February 25, 2016, unless previously converted into shares of restricted common stock. LG has the right to convert the note, until is no longer outstanding  into shares of Common Stock at a price of  sixty-one percent (61%) of the average of the two lowest closing bid prices of the Company’s Common Stock for the twenty trading days preceding  the conversion date.
	On February 24, 2015, the Company issued a Convertible Debentures in the amount of up to $250,000 to a non-related party. The Company received the fund for first tranche of $50,000.  The note carries interest at 12% and is due on the date that is two years from the execution and funding of the note.  The note holders have the right to convert the notes into shares of Common Stock at a price of lessor of (a) 0.01 or (b) sixty percent (60%) of the average of the two lowest closing bid prices of the Company’s Common Stock for the twenty trading days preceding the conversion date.
	Payment Rights Purchase and Sale Agreement
	During January, 2015, the Company entered a Payment Rights Purchase and Sale Agreement with EBF Partners LLC (“EBF”). EBF purchased $204,000 of the merchant sales for $150,000. In exchange for the purchased amount, the Company agreed to enter into a credit card processing agreement with preapproval by EBF with credit card processor. The Company authorized credit card processor to pay to EBF the cash attributable to 23% of each credit card receivable due to the Company, until EBF has received the purchase amount of $204,000. In the event of default, 100% instead of 23% of each credit card receivable will be paid.

BASIS_OF_PRESENTATION_AND_SUMM1

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2014
Basis Of Presentation And Summary Of Significant Accounting Policies Policies
Organization	Organization
	Nutra Pharma Corp. ("Nutra Pharma"), is a holding company that owns intellectual property and operates in the biotechnology industry. Nutra Pharma incorporated under the laws of the state of California on February 1, 2000, under the original name of Exotic-Bird.com.
	Through its wholly-owned subsidiary, ReceptoPharm, Inc. (“ReceptoPharm”), Nutra Pharma conducts drug discovery research and development activities. In October 2009, Nutra Pharma launched its first consumer product called Cobroxin®, an over-the-counter pain reliever designed to treat moderate to severe chronic pain. In May 2010, Nutra Pharma launched its second consumer product called Nyloxin®, an over-the-counter pain reliever that is a stronger version of Cobroxin® and is designed to treat severe chronic pain. In December 2014, we launched Pet Pain-Away, an over-the-counter pain reliever designed to treat pain in cats and dogs.
Basis of Presentation and Consolidation	Basis of Presentation and Consolidation
	The accompanying consolidated financial statements include the results of Nutra Pharma and its wholly-owned subsidiaries Designer Diagnostics Inc. and ReceptoPharm (collectively "the Company", “us”, “we” or “our”). We operate as one reportable segment. All intercompany transactions and balances have been eliminated in consolidation.
Liquidity and Going Concern	Liquidity and Going Concern
	Our Consolidated Financial Statements are presented on a going concern basis, which contemplate the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring, significant losses from operations, and have an accumulated deficit of $44,519,805 at December 31, 2014. In addition, we had respective working capital and stockholders’ deficits at December 31, 2014 of $3,610,206 and $3,594,761, respectively.
	There is substantial doubt regarding our ability to continue as a going concern which is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate.
	As of December 31, 2014, we do not have sufficient cash to sustain our operations for the next year and will require additional financing in order to execute our operating plan and continue as a going concern. Since our sales are not currently adequate to fund our operations, we continue to rely principally on debt and equity funding; however proceeds from such funding have not been sufficient to execute our business plan. Our plan is to attempt to secure adequate funding until sales of our pain products are adequate to fund our operations. We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form. In the event that these financing sources do not materialize, or if we are unsuccessful in increasing our revenues and profits, we will be unable to implement our current plans for expansion, repay our obligations as they become due and continue as a going concern.
	The accompanying Consolidated Financial Statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.
Use of Estimates	Use of Estimates
	The accompanying Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as going concern, the recoverability of inventories and long-lived assets, and the valuation of stock-based compensation and certain debt and warrant liabilities. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known.
Revenue Recognition	Revenue Recognition
	In general, we record revenue when persuasive evidence of an arrangement exists, services have been rendered or product delivery has occurred, the sales price to the customer is fixed or determinable, and collectability is reasonably assured. Provision for sales returns is estimated based on our historical return experience. Revenue is presented net of returns and allowances for returns.
	The Company collects 100% of the cash proceeds from the sale of its product by its distributor, remits a portion of the cash proceeds received back to the distributor and records the sale on a net basis. In the year ended December 31, 2014 and 2013, the Company collected $1,558,124 and $146,832 in gross receipts and recorded $594,505 and $104,835 as net sales.
Accounting for Shipping and Handling Costs	Accounting for Shipping and Handling Costs
	The Company records shipping and handling costs incurred in cost of sales.
Cash and Cash Equivalents	Cash and Cash Equivalents
	We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts
	The Company grants credit without collateral to its customers based on the Company’s evaluation of a particular customer’s credit worthiness. In addition, allowances for doubtful accounts are maintained for potential credit losses based on the age of the accounts receivable and the results of the Company’s periodic credit evaluations of its customers’ financial condition. Accounts receivable are written off after collection efforts have been deemed to be unsuccessful. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against the provision for doubtful accounts expense. The Company generally does not charge interest on accounts receivable.
	Accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts.
Inventories	Inventories
	Inventories, which are stated at the lower of average cost or market, and consist of packaging materials, finished products, and raw venom that is utilized to make the API (active pharmaceutical ingredient). The raw unprocessed venom has an indefinite life for use. The Company regularly reviews inventory quantities on hand.  If necessary it records a provision for excess and obsolete inventory based primarily on its estimates of component obsolescence, product demand and production requirements. Write-downs are charged to cost of goods sold.  We performed evaluations of our inventory during the year ended December 31, 2014 and 2013 and determined no allowances need to be recorded.
Financial Instruments and Concentration of Credit Risk	Financial Instruments and Concentration of Credit Risk
	Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain warrant and convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transactions in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at a measured fair value.
	Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not hold or issue financial instruments for trading purposes. In addition, for the year ended December 31, 2014, no customers accounted for more than 10% of the Company’s total revenues. For the year ended December 31, 2013, there were two customers that accounted for 19.6% and 15.3% of the total revenues, respectively. During 2014 and 2013, the Company purchased 100% of its venom from one vendor.
Derivative Financial Instruments	Derivative Financial Instruments
	The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. For embedded derivatives, the Company uses a Dilution-Adjusted Black-Scholes method to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.
Convertible Debt	Convertible Debt
	The Company bifurcates the embedded derivative element in convertible debt which contain conversion features which are not considered to be conventional convertible debt.  The convertible debt is recorded at the bifurcated amount after reducing the proceeds for the liability related to the embedded call provision which is accounted for separately in the accompanying balance sheets.  After recording the initial amount of the debt, the discount related to the bifurcated embedded derivative is amortized as additional interest expense over the term of the debt with the resulting debt discount being accreted over the term of the note.
Property and Equipment and Long-Lived Assets	Property and Equipment and Long-Lived Assets
	Property and equipment is recorded at cost. Expenditures for major improvements and additions are added to property and equipment, while replacements, maintenance and repairs which do not extend the useful lives are expensed. Depreciation is computed using the straight-line method over the estimated useful lives of the assets of 3 – 7 years.
	Property and equipment consists of the following at December 31,
			2014		2013
	Computer equipment	$	24,208	$	21,918
	Furniture and fixtures		34,757		34,757
	Lab equipment		42,129		42,129
	Telephone equipment		12,421		12,421
	Office equipment – other		16,138		2,629
	Leasehold improvements		73,168		67,417
	Total		202,821		181,271
	Less: Accumulated depreciation and amortization		-173,331		-156,737
	Property and equipment, net	$	29,490	$	24,534
	We review our long-lived assets for recoverability if events or changes in circumstances indicate the assets may be impaired. At December 31, 2014, we believe the carrying values of our long-lived assets are recoverable. Depreciation expense for the years ended December 31, 2014 and 2013 was $16,594 and $14,981, respectively.
Advertising	Advertising
	All advertising costs are expensed as incurred.  Advertising costs were approximately $6,156 and $900 for the years ended December 31, 2014 and 2013, respectively.
Income Taxes	Income Taxes
	We compute income taxes in accordance with Financial Accounting Standard Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 740, Income Taxes (“ASC Topic 740”). Under ASC Topic 740, deferred taxes are recognized for the tax consequences of temporary differences by applying enacted statutory rates applicable to future years to differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities. Also, the effect on deferred taxes of a change in tax rates is recognized in income in the period that included the enactment date. Temporary differences between financial and tax reporting arise primarily from the use of different methods to record bad debts and /or sales returns, and inventory reserves.
	On an annual basis, we evaluate tax positions that have been taken or are expected to be taken in our tax returns to determine if they are more than likely to be sustained if the taxing authority examines the respective position.  As of December 31, 2014 and 2013, we do not believe we have a need to record any liabilities for  uncertain tax positions or provisions for interest or penalties related to such  positions.
	Since inception, we have been subject to tax by both federal and state taxing authorities. Until the respective statutes of limitations expire (which may be as much as 20 years while we have unused net operation losses), we are subject to income tax audits in the jurisdictions in which we operate. The Company’s 2011 to 2014 tax returns are subject to examination by Internal Revenue Services and State Taxing Agency’s.
Stock-Based Compensation	Stock-Based Compensation
	We account for stock-based compensation in accordance with FASB ASC Topic 718, Stock Compensation (ASC Topic 718). ASC Topic 718, which requires that the cost resulting from all share-based transactions be recorded in the financial statements over the respective service periods. It establishes fair value as the measurement objective in accounting for share-based payment arrangements and requires all entities to apply a fair-value-based measurement in accounting for share-based payment transactions with employees. The statement also establishes fair value as the measurement objective for transactions in which an entity acquires goods or services from non-employees in share-based payment transactions.
Net Loss Per Share	Net Loss Per Share
	Net loss per share is calculated in accordance with ASC Topic 260, Earnings per Share. Basic loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted loss per share is calculated by dividing net loss by the weighted average number of common shares and dilutive common stock equivalents outstanding. During periods in which we incur losses, common stock equivalents, if any, are not considered, as their effect would be anti-dilutive or have no effect on earnings per share. Any common shares issued as of a result of the exercise of stock options and warrants would come from newly issued common shares from our remaining authorized shares. As of December 31, 2014 and 2013, the following items were not included in dilutive loss as the effect is anti-dilutive:
			2014		2013
	Options and warrants		64,266,667		154,916,667
	Convertible notes payable		56,817,342		98,506,398
	Total		121,084,009		253,423,065
Reclassifications	Reclassifications
	Certain amounts in the 2013 Consolidated Financial statements have been reclassified to conform to the current period presentation.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	ASU 2014 - 09
	In June 2014, FASB issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers”. The update gives entities a single comprehensive model to use in reporting information about the amount and timing of revenue resulting from contracts to provide goods or services to customers. The proposed ASU, which would apply to any entity that enters into contracts to provide goods or services, would supersede the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance throughout the Industry Topics of the Codification. Additionally, the update would supersede some cost guidance included in Subtopic 605-35, Revenue Recognition – Construction-Type and Production-Type Contracts. The update removes inconsistencies and weaknesses in revenue requirements and provides a more robust framework for addressing revenue issues and more useful information to users of financial statements through improved disclosure requirements. In addition, the update improves comparability of revenue recognition practices across entities, industries, jurisdictions, and capital markets and simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. The update is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. We are currently reviewing the provisions of this ASU to determine if there will be any impact on our results of operations, cash flows or financial condition.
	ASU 2014-12
	In June 2014, FASB issued Accounting Standards Update (“ASU”) No. 2014-12, “Compensation – Stock Compensation ( Topic 718 ); Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period”. The amendments in this ASU apply to all reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target that affects vesting could be achieved after the requisite service period. The amendments require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Topic 718 as it relates to awards with performance conditions that affect vesting to account for such awards. For all entities, the amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted. The effective date is the same for both public business entities and all other entities.
	Entities may apply the amendments in this ASU either (a) prospectively to all awards granted or modified after the effective date or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. If retrospective transition is adopted, the cumulative effect of applying this Update as of the beginning of the earliest annual period presented in the financial statements should be recognized as an adjustment to the opening retained earnings balance at that date. Additionally, if retrospective transition is adopted, an entity may use hindsight in measuring and recognizing the compensation cost. We are currently reviewing the provisions of this ASU to determine if there will be any impact on our results of operations, cash flows or financial condition.
	ASU 2014-15
	In August 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-15 on “Presentation of Financial Statements Going Concern (Subtopic 205-40) – Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. Currently, there is no guidance in U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. The amendments in this Update provide that guidance. In doing so, the amendments are intended to reduce diversity in the timing and content of footnote disclosures. The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in this Update are effective for public and non-public entities for annual periods ending after December 15, 2016. Early adoption is permitted. We are currently reviewing the provisions of this ASU to determine if there will be any impact on our results of operations, cash flows or financial condition.
	All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

BASIS_OF_PRESENTATION_AND_SUMM2

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Property and Equipment and Long-Lived Assets	Property and equipment consists of the following at December 31,
			2014		2013
	Computer equipment	$	24,208	$	21,918
	Furniture and fixtures		34,757		34,757
	Lab equipment		42,129		42,129
	Telephone equipment		12,421		12,421
	Office equipment – other		16,138		2,629
	Leasehold improvements		73,168		67,417
	Total		202,821		181,271
	Less: Accumulated depreciation and amortization		-173,331		-156,737
	Property and equipment, net	$	29,490	$	24,534
Net Loss Per Share	As of December 31, 2014 and 2013, the following items were not included in dilutive loss as the effect is anti-dilutive:
			2014		2013
	Options and warrants		64,266,667		154,916,667
	Convertible notes payable		56,817,342		98,506,398
	Total		121,084,009		253,423,065

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair value measurement	The following table summarizes our financial instruments measured at fair value as of December 31, 2014 and 2013:
			Fair Value Measurements at December 31, 2014
	Liabilities:		Total		Level 1		Level 2		Level 3
	Warrant liability	$	186,549	$	-	$	-	$	186,549
	Convertible notes at fair value	$	330,277	$	-	$	-	$	330,277
			Fair Value Measurements at December 31, 2013
	Liabilities:		Total		Level 1		Level 2		Level 3
	Warrant liability	$	323,172	$	-	$	-	$	323,172
	Convertible notes at fair value	$	767,056	$	-	$	-	$	767,056
Changes in fair value measurements	The following table shows the changes in fair value measurements using significant unobservable inputs (Level 3) during the years ended December 31, 2014 and 2013:
	Description		2014		2013
	Beginning balance	$	323,172	$	18,727
	Purchases, issuances, and settlements		18,551		243,147
	Day one loss on value of hybrid instrument		-		729,093
	Total gain included in earnings (1)		-155,174		-667,795
	Ending balance	$	186,549	$	323,172
Debentures	The following table summarizes the significant terms of each of the debentures for which the entire hybrid instrument is recorded at fair value as of December 31, 2014 and 2013:
	Debenture		Face		Interest		Default		Conversion Price - Lower of Fixed Price or Percentage of VWAP for Look-back Period		Look-back
	Issuance Year		Amount		Rate		Interest				Period
							Rate		Anti-Dilution	%
									Adjusted Price
	2014		215,386		8%-20%		n/a		$0.0028-$0.0050	50%-85%	10 to 30 Days
	2013		564,376		8%-20%		n/a		$0.0036-$0.0064	50%-85%	10 to 30 Days
Convertible Notes	The following table shows the changes in fair value measurements using significant unobservable inputs (Level 3) during the years ended December 31, 2014 and 2013 for the Convertible Notes:
			Years Ended December 31,
			2014		2013
	Description
	Beginning balance	$	767,057	$	588,091
	Purchases, issuances, and settlements		162,311		751,419
	Day one loss on value of hybrid instrument		423,340		1,656,802
	(Gain) loss from change in fair value		-78,527		-582,423
	Conversion to common stock		-943,904		-1,646,832
	Ending balance	$	330,277	$	767,057

INVENTORIES_Tables

INVENTORIES (Tables)	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Schedule of inventories	At December 31, 2014 and 2013, inventories were as follows:
			2014		2013
	Raw Materials	$	16,805	$	5,000
	Finished Goods		30,140	$	-
	Total Inventories	$	46,945	$	5,000

DUE_TO_OFFICERS_Tables

DUE TO OFFICERS (Tables)	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Due to officers	At December 31, 2014 and December 31, 2013, the balance due to officers consisted of the following:
			31-Dec-14		December 31,
					2013
	An unsecured demand loan from our President and CEO, Rik Deitsch. The loan bears interest at 4%. The loan balance at December 31, 2014 and 2013, respectively, includes accrued interest payable of $369,983 and $349,466.	$	411,411	$	566,399
	A loan from Paul Reid, the former President of ReceptoPharm bearing interest at a rate of 5% per annum, due on demand and secured by certain intellectual property of ReceptoPharm  having a zero cost at December 31, 2014 and 2013. The accrued interest at December 31, 2014 and 2013 was $49,638 and $43,363, respectively.		129,466		123,189
	Ending balances	$	540,877	$	689,588

OTHER_DEBT_Tables

OTHER DEBT (Tables)	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Other debt	Other debt (Both short-term and long term) consists of the following at December 31, 2014 and 2013:
			2014		2013
	Note payable – Related Party   (1)	$	120,000	$	180,000
	Notes payable – Non Related Parties  (2)		540,644		412,182
	Convertible notes payable, at fair value (3)		330,277		767,056
	Ending balances	$	990,921	$	1,359,238

STOCKHOLDERS_DEFICIT_Tables

STOCKHOLDERS' DEFICIT (Tables)	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Stockholders' deficit	Following the assignment of Michael McDonald’s debt of $92,310 in June 2014, Coventry made the following conversions of a total of 13,084,856 shares of the company’s restricted stock satisfying $36,924 of the note with a fair value of $122,725 (See Note 6).
	Date	Number of		Fair Value of
		shares converted		Debt Converted
	6/18/14	8,781,389	$	92,816
	7/2/14	4,293,467	$	29,909
	During May and June, 2014, the two convertible Notes holders made the following conversions of a total of 33,226,382 shares of the company’s restricted stock satisfying the notes in the amount of $92,000 with a fair value of $177,093 on the dates of conversions (See Note 6).
	Date	Number of		Fair Value of
		shares converted		Debt Converted
	5/30/14	23,529,412	$	79,632
	6/16/14	4,545,455	$	45,820
	6/14/14	5,151,515	$	51,641
	During February and June, 2014, $23,000 and $10,000 of the convertible notes were assigned to third parties with a conversion price at $0.005 and $0.002 per share, respectively. The conversions for a total of 9,600,000 shares of the company’s restricted stock were made as followings in satisfying the notes of $33,000 at the fair value of $65,982 (See Note 6).
	Date	Number of		Fair Value of
		shares converted		Debt Converted
	2/10/14	4,600,000	$	30,726
	6/14/14	5,000,000	$	35,256
	Following the agreements with Coventry Enterprises, LLC (see Note 6) for $100,000 and $70,000 in September 2013, Coventry made the following conversions for a total of 51,460,632 shares of the company’s restricted stock during the year ended December 31, 2014 satisfying the Notes in full (See note 6):
	Date	Number of		Fair Value of
		shares converted		Debt Converted
	3/11/14	23,376,623	$	187,119
	3/12/14	15,584,415	$	123,641
	6/12/14	12,499,594	$	103,142
	Following the agreements with Coventry Enterprises, LLC (see Note 6) for $80,000, Coventry made the following conversions for a total of 15,119,481 shares of the company’s restricted stock during the first quarter of 2013 satisfying the notes in full and recorded a loss of $65,039 (See Note 6):
	Date	Number of		Fair Value of
		shares converted		Debt Converted
	1/21/13	4,032,258	$	37,619
	2/11/13	5,405,405	$	42,510
	3/20/13	5,681,818	$	40,414
	Following the agreement with Coventry Enterprises, LLC (see Note 6) for $88,500, Coventry made the following conversions for a total of 31,416,845 shares of the company’s restricted stock during the second quarter of 2013 satisfying the notes in full:
	Date	Number of		Fair Value of
		shares converted		Debt Converted
	4/17/13	7,133,333	$	49,586
	5/16/13	11,101,694	$	64,930
	6/12/13	13,181,818	$	70,130
	During June and August, 2013, one of the convertible Notes holders made the following conversions of a total of 34,254,004 shares of the company’s restricted stock satisfying the notes in the amount of $125,000 with a fair value of $317,391 on the date of conversion (See Note 6).
	Date	Number of		Fair Value of
		shares converted		Debt Converted
	6/25/13	22,058,882	$	188,352
	8/30/13	12,195,122	$	129,039
	During August and September, 2013, $150,000 of the convertible notes were assigned to third parties in the form bearing interest of 8% annum at with a conversion price for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 to 20 trading days immediately preceding the Conversion Date. Immediately following the assignments, the conversions for a total of 64,052,862 shares of the company’s restricted stock were made as followings in satisfying the notes of $150,000 at the fair value of $475,519(See Note 6).
	Date	Number of		Fair Value of
		shares converted		Debt Converted
	8/28/13	22,026,431	$	167,493
	9/3/13	20,000,000	$	163,909
	9/4/13	22,026,431	$	144,117

STOCK_OPTIONS_AND_WARRANTS_Tab

STOCK OPTIONS AND WARRANTS (Tables)	12 Months Ended
	Dec. 31, 2014
Other Liabilities Disclosure [Abstract]
Summary of warrants outstanding	A summary of warrants outstanding in conjunction with private placements of common stock were as follows during the year ended December 31, 2014 and 2013:
			Number		Weighted average
			of shares		exercise price
	Balance December 31, 2012		57,256,667	$	0.1
	Exercised		-		-
	Issued		98,600,000	$	0.01 – 0.10
	Forfeited/Expired		-940,000		-
	Balance December 31, 2013		154,916,667	$	0.082
	Exercised		-		-
	Issued		16,000,000	$	0.03
	Forfeited		-106,650,000		-
	Balance December 31, 2014		64,266,667	$	0.081
Summary of fixed-price warrants outstanding	The following table summarizes information about fixed-price warrants outstanding as of December 31, 2014 and 2013:
			Exercise		Number	Weighted		Weighted
			Price		Outstanding	Average		Average
						Contractual		Exercise
						Life		Price
	2014	$	0.01-0.03		64,266,667	2.76 years	$	0.081
	2013	$	0.01-0.10		154,916,667	1.97 years	$	0.082

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Summary of income tax expense	The Company’s tax expense differs from the “expected” tax expense for the years ended December 31, 2014 and 2013, (computed by applying the Federal Corporate tax rate of 34% to loss before taxes and 5.5% for Florida State Corporate Taxes, the blended rate used was 37.63%), are approximately as follows:
			December 31,
			2014		2013
	Computed "expected" tax expense (benefit) - Federal	$	-813,848	$	-1,346,076
	Computed "expected" tax expense (benefit) - State		-139,314		-322,564
	Permeate differences		797,895		1,010,838
	Change in valuation allowance		155,267		657,802
		$	-	$	-
Summary of deferred income tax assets	Current portion of net deferred income tax assets:		2014		2013
	Allowance for doubtful accounts	$	-	$	242,000
	Reserve for inventory obsolescence		-		313,925
	Accrued salary		155,267		101,877
	Subtotal		155,267		657,802
	Valuation allowance		-155,267		-657,802
	Current net deferred income tax asset		-		-
	Non- current portion of net deferred income tax asset
	Net operating loss carryforwards		10,739,524		10,584,257
	Valuation allowance		-10,739,524		-10,584,257
	Non-current net deferred income tax asset	$	-	$	-

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule of future minimum payments under these lease agreements	Future minimum payments under these lease agreements, including the extension period, are approximately as follows:
	Years ended December 31,		Amounts
	2015	$	120,218
	2016		79,892
	2017		45,249
	Total	$	245,359

BASIS_OF_PRESENTATION_AND_SUMM3

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Total	$202,821	$181,271
Less: Accumulated depreciation and amortization	-173,331	-156,737
Property and equipment, net	29,490	24,534
Computer Equipment [Member]
Total	24,208	21,918
Furniture and fixtures [Member]
Total	34,757	34,757
Lab equipment [Member]
Total	42,129	42,129
Telephone equipment [Member]
Total	12,421	12,421
Office equipment other [Member]
Total	16,138	2,629
Leasehold improvements [Member]
Total	$73,168	$67,417

BASIS_OF_PRESENTATION_AND_SUMM4

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Accounting Policies [Abstract]
Options and warrants	$64,266,667	$154,916,667
Convertible notes payable	56,817,342	98,506,398
Total	$121,084,009	$253,423,065

BASIS_OF_PRESENTATION_AND_SUMM5

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Accumulated deficit	$44,519,805
Working capital	3,610,206
Stockholders' deficits	3,594,761
Gross receipts	1,558,124	146,832
Net sales	594,505	104,835
Depreciation expense	16,594	14,981
Advertising costs	$6,156	$900
Customer [Member]
Number of customers		2
Percentage of revenue for customer one		19.60%
Percentage of revenue for customer two		15.30%
Percentage of venom from one vendor	100.00%	100.00%
Maximum percenatge of revenue allowed	10.00%

FAIR_VALUE_MEASUREMENTS_Detail

FAIR VALUE MEASUREMENTS (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Warrant liability	$186,549	$323,172
Convertible notes at fair value	330,277	767,056
Fair Value, Inputs, Level 1 [Member]
Warrant liability
Convertible notes at fair value
Fair Value, Inputs, Level 2 [Member]
Warrant liability
Convertible notes at fair value
Fair Value, Inputs, Level 3 [Member]
Warrant liability	186,549	323,172
Convertible notes at fair value	$330,277	$767,056

FAIR_VALUE_MEASUREMENTS_Detail1

FAIR VALUE MEASUREMENTS (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Fair Value Disclosures [Abstract]
Beginning balance	$323,172	$18,727
Purchases, issuances, and settlements	18,551	243,147
Day one loss on value of hybrid instrument		729,093
Total gain included in earnings (1)	-155,174	-667,795
Ending balance	$186,549	$323,172

FAIR_VALUE_MEASUREMENTS_Detail2

FAIR VALUE MEASUREMENTS (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Debenture issue year	2014	2013
Face Amount	$215,386	$564,376
Default Interest Rate	-	-
Minimum [Member]
Interest Rate	8.00%	8.00%
Anti-Dilution Adjusted price	$0.00	$0.00
Percentage of hybrid debenture	50.00%	50.00%
Look back period	10 days	10 days
Maximum [Member]
Interest Rate	20.00%	20.00%
Anti-Dilution Adjusted price	$0.01	$0.01
Percentage of hybrid debenture	85.00%	85.00%
Look back period	30 days	30 days

FAIR_VALUE_MEASUREMENTS_Detail3

FAIR VALUE MEASUREMENTS (Details 3) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Purchases, issuances, and settlements	$18,551	$243,147
Day one loss on value of hybrid instrument		729,093
(Gain) loss from change in fair value	-155,174	-667,795
Ending balance	186,549	323,172	18,727
Convertible Notes Payable [Member]
Beginning balances	767,057	588,091
Purchases, issuances, and settlements	162,311	751,419
Day one loss on value of hybrid instrument	423,340	1,656,802
(Gain) loss from change in fair value	-78,527	-582,423
Conversion to common stock	-943,904	-1,646,832
Ending balance	$330,277	$767,057

FAIR_VALUE_MEASUREMENTS_Detail4

FAIR VALUE MEASUREMENTS (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Expected dividends	0.00%
Exercise price	$0
Minimum [Member]
Risk-free rate		0.25%
Expected volatility		161.00%
Maximum [Member]
Risk-free rate		1.65%
Expected volatility		174.00%

INVENTORIES_Details

INVENTORIES (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Inventory Disclosure [Abstract]
Raw Materials	$16,805	$5,000
Finished Goods	30,140
Total Inventories	$46,945	$5,000

SETTLEMENT_OF_ACCOUNTS_AND_NOT1

SETTLEMENT OF ACCOUNTS AND NOTE PAYABLE (Details Narratives) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Payables and Accruals [Abstract]
Restricted stock		15,119,481
Loss on settlement and the change in fair value of derivatives		$65,039
Recorded loss of selling expense	1,164,000
Change in fair value of derivatives		4,885
Total loss settlement on date	$15,472

DUE_TO_OFFICERS_Details_Narrat

DUE TO OFFICERS (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Loan borrowed	$86,464	$151,718
Loan repaid	161,969	53,600
Loan 1 [Member]
Accrued interest payable	369,983	349,466
Loan 2 [Member]
Accrued interest payable	$49,638	$43,363

DUE_TO_OFFICERS_Details

DUE TO OFFICERS (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Notes to Financial Statements
Unsecured demand loan	$411,411	$566,399
Secured loan	129,466	123,189
Ending balances	$540,877	$689,588

OTHER_DEBT_Details

OTHER DEBT (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Debt Disclosure [Abstract]
Note payable - Related Party (1)	$120,000	$180,000
Notes payable - Non Related Parties (2)	540,644	412,182
Convertible notes payable-short term, at fair value (3)	330,277	767,056
Ending balances	$990,921	$1,359,238

OTHER_DEBT_Details_Narrative

OTHER DEBT (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Debt balance	$879,608
Accrued interest	148,558
Repaid a total	60,000
Director accrued interest	157,128	121,137
Promissory note balance	540,644	412,182
Amortization	13,054	3,977
Debt discount		3,977
Owed approximately	55,410
Convertible loans balance	330,277	767,056
Accrued interest payable	4,163	6,664
Common stock shares issued	33,226,382	34,254,004
Satisfying the notes in the amount	92,000	125,000
Fair value	177,093	317,391
Non-related parties	33,000	150,000
Convertible note payable fair value	125,980
Fair value	16,303
Convertible note payable fair value	87,518
Fair value	65,836
Remaining balance	100,000
Fair value	40,627
Convertible note payable fair value	18,672
Fair value	36,450
Remaining balance	55,386
Fair value	110,159
Convertible note payable fair value	10,679
Funds was received	15,000
Convertible note payable fair value	18,104
Non-related party [Member]
Debt balance	131,072
Repaid a total	18,926
Amortization	2,200
Interest expense	$5,862

STOCKHOLDERS_DEFICIT_Details

STOCKHOLDERS' DEFICIT (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
June, 18 2014 [Member]
Number of shares converted	8,781,389
Fair Value of Debt Converted	$92,816
July, 2 2014 [Member]
Number of shares converted	4,293,467
Fair Value of Debt Converted	29,909
May, 30 2014 [Member]
Number of shares converted	23,529,412
Fair Value of Debt Converted	79,632
June, 16 2014 [Member]
Number of shares converted	4,545,455
Fair Value of Debt Converted	45,820
June, 14 2014 [Member]
Number of shares converted	5,151,515
Fair Value of Debt Converted	51,641
February, 10 2014 [Member]
Number of shares converted	4,600,000
Fair Value of Debt Converted	30,726
June, 14 2014 One [Member]
Number of shares converted	5,000,000
Fair Value of Debt Converted	35,256
March, 11 2014 One [Member]
Number of shares converted	23,376,623
Fair Value of Debt Converted	187,119
March, 12 2014 One [Member]
Number of shares converted	15,584,415
Fair Value of Debt Converted	123,641
June, 12 2014 [Member]
Number of shares converted	12,499,594
Fair Value of Debt Converted	103,142
January, 21 2013 [Member]
Number of shares converted	4,032,258
Fair Value of Debt Converted	37,619
February, 11 2013 [Member]
Number of shares converted	5,405,405
Fair Value of Debt Converted	42,510
March, 20 2013 [Member]
Number of shares converted	5,681,818
Fair Value of Debt Converted	40,414
April, 17 2013 [Member]
Number of shares converted	7,133,333
Fair Value of Debt Converted	49,586
May, 16 2013 [Member]
Number of shares converted	11,101,694
Fair Value of Debt Converted	64,930
June, 12 2013 [Member]
Number of shares converted	13,181,818
Fair Value of Debt Converted	70,130
June, 25 2013 [Member]
Number of shares converted	22,058,882
Fair Value of Debt Converted	188,352
August, 30 2013 [Member]
Number of shares converted	12,195,122
Fair Value of Debt Converted	129,039
August, 28 2013 [Member]
Number of shares converted	22,026,431
Fair Value of Debt Converted	167,493
September, 3 2013 [Member]
Number of shares converted	20,000,000
Fair Value of Debt Converted	163,909
September, 4 2013 [Member]
Number of shares converted	22,026,431
Fair Value of Debt Converted	$144,117

STOCKHOLDERS_DEFICIT_Details_N

STOCKHOLDERS' DEFICIT (Details Narrative) (USD $)	4 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Equity [Abstract]
Equity compensation charge	$70,902	$1,929	$70,902
Equity compensation charge	8,351	5,918	8,351
Equity compensation charge	8,446	22,938	8,446
Equity compensation charge	61,019		61,019
Equity compensation charge one			17,500
Equity compensation charge two			267,000
Equity compensation charge three			24,000
Equity compensation charge four			34,350
Equity compensation charge five			8,400
Equity compensation charge six			420
Equity compensation charge seven			85,500
Equity compensation charge eight			8,400
Equity compensation charge nine			10,500
Equity compensation charge ten			27,000
Equity compensation charge elevan			50,000
Equity compensation charge twelve			14,000
Equity compensation charge thirteen			108,534	80,216
Equity compensation charge fourteen			28,646	40,104
Remaining compensation cost		2,981	5,208
Remaining compensation cost		2,754	15,625
Remaining compensation cost		2,981	3,533
Remaining compensation cost		32,899	21,625
Restricted stock		324,552
Restricted stock shares		54,092,000
Amortization		13,054	3,977
Restricted stock Issued		3,775,000
Restricted stock fair value		26,048
Issuance of restricted common stock to consultant for services		2,000,000
Fair value of restricted common stock issued for services		12,000
Non-vested shares			125,000
Restricted stock of conversion		2,857,143
Fairvalue of restricted stock for conversion		$14,286
Restricted stock of conversion one		51,460,632

STOCK_OPTIONS_AND_WARRANTS_Det

STOCK OPTIONS AND WARRANTS (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Beginnings balance, Number of shares	154,916,667	57,256,667
Number of shares Exercised
Number of shares, Issued	16,000,000	98,600,000
Number of shares, Forfeited/Expired	-106,650,000	-940,000
Endings balance Number of shares	64,266,667	154,916,667
Beginnings balance, Weighted average exercise price	$0.08	$0.10
Weighted average exercise price, Exercised
Weighted average exercise price, Issued	$0.03
Weighted average exercise price, Forfeited/Expired
Ending balance, Weighted average exercise price	$0.08	$0.08
Minimum [Member]
Weighted average exercise price, Issued		$0.01
Maximum [Member]
Weighted average exercise price, Issued		$0.10

STOCK_OPTIONS_AND_WARRANTS_Det1

STOCK OPTIONS AND WARRANTS (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Other Liabilities Disclosure [Abstract]
Exercise Price lower limit	$0.01	$0.01
Exercise price upper limit	$0.03	$0.10
Number Outstanding	64,266,667	154,916,667
Weighted Average Contractual Life	2 years 9 months 4 days	1 year 11 months 19 days
Weighted Average Exercise Price	$0.08	$0.08

STOCK_OPTIONS_AND_WARRANTS_Det2

STOCK OPTIONS AND WARRANTS (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014
Other Liabilities Disclosure [Abstract]
Aggregate intrinsic value	$0
Intrinsic value calculation is based	$0.01

INCOME_TAXES_Details_1

INCOME TAXES (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Computed "expected" tax expense (benefit) - Federal	($813,848)	($1,346,076)
Computed "expected" tax expense (benefit) - State	-139,314	-322,564
Permeate differences	797,895	1,010,838
Change in valuation allowance	155,267	657,802
Income tax expense

INCOME_TAXES_Details_2

INCOME TAXES (Details 2) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Allowance for doubtful accounts		$242,000
Reserve for inventory obsolescence		313,925
Accrued salary	155,267	101,877
Subtotal	155,267	657,802
Valuation allowance	-155,267	-657,802
Current net deferred income tax asset
Non- current portion of net deferred income tax asset
Net operating loss carryforwards	10,739,524	10,584,257
Valuation allowance	-10,739,524	-10,584,257
Non-current net deferred income tax asset

INCOME_TAXES_Details_Narrative

INCOME TAXES (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$29,800,000
Change in valuation allowances	155,000	658,000
Accumulated deficit	($44,519,805)	($41,986,820)

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES (Details 1) (USD $)	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
2015	$120,218
2016	79,892
2017	45,249
Total	$245,359

COMMITMENTS_AND_CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]
Incurred rent expense	$119,215	$114,889